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0 SUMMARY 
 
Background 
Bacterial wound infections (especially those involving biofilms) represent a major challenge 
to healthcare, and are responsible for significant morbidity and mortality. Owing to the rise 
in antimicrobial resistance, there is renewed interest in alternative antimicrobial agents for 
treatment of wound infections, where prevention of colonisation largely relies on topically-
applied biocides.  
 
Objectives 
The aim was to investigate the antibacterial activity of acetic acid (AA), following on from 
preliminary testing, and small-scale use on burns patients. This led on to the testing of 
additional products (SurgihoneyRO (SH1) and blue light (BL)), for which no prior evaluation 
(against biofilms) had been performed. 
Methods 
In vitro experiments were performed to test the antimicrobial activity of the agents against 
bacteria growing planktonically and as biofilms. Comparisons were also made to a range of 
commercially-available antimicrobial dressings (AMDs) and medical honeys. Results were 
assessed through measurement of biofilm biomass, and biofilm seeding using a crystal 
violet assay.  
 
Results 
All agents were effective against biofilms of a large panel of clinically important nosocomial 
wound pathogens. AA could prevent biofilm formation at concentrations of ≤0.31%, and 
eradication of mature biofilms was observed after 3 hours of exposure. SH1 prevented 
biofilm formation of 16 bacterial isolates at dilutions (from neat) of 1:2 to 1:128. Mature 
biofilms were highly susceptible to BL, with significant reduction in seeding observed for all 
isolates.  
Conclusions 
All of the test antimicrobial agents have shown promise in vitro for the treatment and 
eradication of biofilm infections caused by a range of important wound pathogens. 
However, there are still some unanswered questions. Clinical trials are planned, and it 
remains to be seen whether the in vitro findings will translate to the in vivo setting, where 
there is a complex interplay between host and pathogen, and many other factors that 
influence biofilm presence and persistence.   
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1 BACKGROUND 
 
Bacteria may exist in one of two growth states; planktonically (free-floating), or aggregated 
(in a biofilm) [1]. Cells within a biofilm can be attached to each other (in multicellular 
aggregates which may themselves not be directly adhered to a surface), or adhered to a 
surface [2]. This trait enables bacteria to adapt to environmental change, and affords 
higher resistance to adverse physiological conditions [3]. Consequently biofilms are 
abundant in natural and engineered environments, where they can have both beneficial 
and detrimental effects (from an anthropocentric point of view).  
The beneficial aspects of biofilms include their use in wastewater treatment plants (as 
filters and bioreactors in the treatment process) [4], bioremediation (e.g. biofilms can 
metabolise organic pollutants) [5], and promotion of plant growth (owing to the presence 
of growth-promoting rhizobacteria in plant-associated  biofilms) [6]. They are also 
important in marine environments, with bacteria often the first microorganisms to colonise 
a surface, leading to the rapid succession of colonisation by higher organisms including 
barnacles. Biofilms can regulate the settlement/attachment of higher sessile organisms, 
thus potentially reducing the chance of biofouling [7]. Since they readily colonise both 
biotic and abiotic surfaces, biofilms can also be detrimental, causing bio-deterioration in 
engineered systems, slowing down ships (due to the accumulation of biofilm on the hull), 
and the bio-fouling of food processing equipment [3].  
Although it can be argued that the majority of our beneficial bacteria may exist as biofilms 
in the body (e.g. the protective microbiome found in the large intestine), biofilms are also 
responsible for the majority of chronic infections [8]. These  infections, typically of mixed 
microbial aetiology [9] are important clinically for a range of conditions (e.g. foreign-body 
related, otitis media, chronic wounds, and lung infections) [10], and it is estimated that at 
least 60% of chronic infections involve a biofilm [11,12]. The longer a biofilm persists, the 
greater the risks are that the patient will develop invasive systemic infections [13], such as 
bacteraemia. Furthermore, a large evidence base now exists showing that biofilms exist in 
the majority of non-healing chronic wounds [14,15], and are associated with delayed 
healing [16,17] (Figure 1). Indeed, several authors [14,18,19] advocate that the presence of 
a biofilm should be considered for any non-healing wound. 
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Figure 1: Panel of photographs showing clinical biofilm infections (all taken from  
[30]) 1: Chronic foot ulcer infected with P. aeruginosa, 2: large ischaemic foot 
ulcer infected with P. aeruginosa and coliforms, 3: hand of a Ugandan woman 
with an infected deep traumatic wound (no microbiological results), 4: 
Amputation site with Streptococcus agalactiae infection.  
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1.1 The biofilm formation process  
 
The switch from planktonic to sessile existence (i.e. biofilm formation) in bacteria is 
controlled by a number of species-specific environmental and genetic factors, but generally 
begins with contamination and the initial adsorption and attachment of bacteria to a 
surface or to each other.   
 
In Pseudomonas aeruginosa, biofilm formation can occur in just six hours [14], and 
established biofilms may be present by 24 hours [14]. Here, the initial reversible 
attachment of bacteria to a surface occurs due to the action of the flagella (which aid in the 
mobility of the bacterium), type IV pili, fimbria, extracellular DNA, and the Psl 
exopolysaccharide. The pilli are constructed from a single protein subunit (PilA), and 
mutants lacking the required genes to form flagella and pilli/fimbriae are poor at surface 
attachment and biofilm formation [20].   
 
After reversible attachment, cells may undergo irreversible attachment (where they attach 
by more than just their ‘poles’). This involves surface proteins (e.g. Lipopolysaccharide-A in 
P. aeruginosa which acts to increase hydrophobicity of the cell surface, which enhances 
adhesion to hydrophobic surfaces), as well as intracellular secondary messenger molecules 
such as bis-(3′-5′)-cyclic dimeric guanosine monophosphate (c-di-GMP) and cyclic 
adenosine monophsphate (cAMP ) [21].  Once attached, the cells produce matrix, and the 
biofilm expands, matures and disperses (where planktonic cells are released from the 
mature biofilm to find new sites for colonisation) (Figure 2).  
 
The matrix (referred to as the extracellular polymeric substance (EPS)), is made of 
polysaccharides, proteins, lipids and extracellular DNA [22], and enables the biofilm to 
withstand adverse conditions. The EPS layer also houses quorum sensing signalling (QS) 
molecules, extracellular enzymes, and metabolic products [21].  Alginate is a key 
component of the biofilm matrix in P. aeruginosa and is overproduced by isolates 
associated with cystic fibrosis (mucoid phenotype) [23]. Dispersal of planktonic cells from 
the mature biofilm is controlled through QS and three interconnected gene systems: the 
Las system; the Rhl system; and the Pqs system [24]. In order to encourage detachment of 
the bacteria and dispersal to new sites, P. aeruginosa also produces an alginate lyase 
enzyme which cleaves the alginate into short chain polymers, and resulting in detachment 
of planktonic cells [25]  
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The physiology of biofilm-containing cells differs considerably to the physiology of 
planktonic cells. The complex structure of biofilms affords them greater ability to withstand 
adverse conditions (e.g. high osmotic stress, low nutrients, low oxygen availability, 
antibiotics and the host immune response). Furthermore, bacteria contained within 
biofilms have reduced rates of metabolism [11], and consequently are harder to treat and 
eradicate than their planktonic counterparts [26], requiring concentrations of systemic 
antimicrobials 10-1,000 times higher than those needed to treat the same species of 
planktonic bacteria [27]. Despite the administration of antibiotics, treatment is often 
ineffective due to the high circulating levels of antimicrobial resistance in common wound 
pathogens, the existence of metabolically-dormant persister cells (which can recrudesce 
and repopulate the biofilm [28]), and the presence and mixed microbial aetiology of 
biofilms (resulting in imperfect antibiotic coverage) [14,29]. Furthermore, chronic wounds 
often have poor blood supply [14,30], leading to poor delivery of systemic antimicrobials.  
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Figure 2: The stages of biofilm formation, maturation and dispersion (modified from the original version [31] by rearranging the figure, and adding text)  
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1.2 Therapeutic anti-biofilm strategies 
Therapeutic anti-biofilm strategies intend to prevent, remove and kill bacterial biofilms 
(Table 1), and target the bacteria forming the biofilm, but also aim to suppress the biofilm 
through simultaneous use of other strategies, in what is referred to as ‘biofilm-based 
wound care’. Below is a review of a few of these strategies.  
To prevent biofilms, the contamination and adhesion/colonisation of wounds with bacteria 
must be prevented e.g. via aseptic surgical techniques, as well as the use of barrier 
dressings, which aim to keep the wound clean and free from bacteria (physical dressings), 
and in most cases contain an antimicrobial agent (more detail will be provided in the next 
section). Other preventative measures may involve the use of anti-deposition agents to 
interfere with EPS production, QS inhibitors e.g. hamamelitannin (although limited since QS 
signal molecules vary between bacterial species, and only 50% share the same autoinducer 
[31]), probiotics, and lytic bacteriophages (which carry enzymes to degrade EPS [32]) (Table 
1). For example, DispersinB (a matrix-degrading enzyme of Aggregatibacter 
actinomycetemcomitans), can inhibit formation, induce detachment, and sensitize biofilms 
to antibiotics and host defences [33].  
Once biofilm infection is established (which is the case seen with the majority of clinical 
wounds), most of the clinical management relies on physical debridement of the wound to 
remove the biofilm, in conjunction with systemic antimicrobials and topical antiseptics to 
kill the remaining bacteria. The terminology used to describe antimicrobial agents can be 
confusing. Antimicrobial agents include those effective against bacteria, fungi, viruses, 
parasites and spores. Within this umbrella term lie the antibiotics (‘naturally occurring or 
synthetic organic substances which inhibit or destroy selective bacteria, generally at low 
concentrations’), the biocides (‘broad-spectrum chemical agents that inactivate 
microorganisms’), and the antiseptics (‘biocides or products that destroy or inhibit the 
growth of microorganisms in or on living tissue’)[34].  
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Aim Description 
Prevention of biofilm formation 
Prevent contamination  
- Aseptic (surgical) 
procedures 
The risks of contamination can be reduced through careful 
attention to aseptic techniques in surgery, and the use of barrier 
wound dressings (to mimic the function of intact skin and keep 
the wound sterile) 
- Barrier dressings 
Prevent colonisation  
Prevent biofilm development/EPS expression via 
- Anti–deposition (anti-
attachment) agents  
e.g. Lactoferrin and xylitol.  
 Lactoferrin has been demonstrated in vitro to prevent 
the adhesion of P. aeruginosa to a surface [35]. 
 Some evidence exists that xylitol (a sugar alcohol) can 
inhibit attachment and biofilm growth of oral biofilm 
bacteria [36]. 
- Quorum sensing (QS) 
inhibitors  
QS signals can be degraded (using quorum quenching enzymes) 
or inhibited (using QS analogues). For example, the N-acyl 
homoserine lactone (AHL) signalling molecule can be degraded by 
specific lactonases acylases [37]. 
- Probiotics Lactobacillus has been shown to outcompete and inhibit 
pathogenic activity of P. aeruginosa and Staphylococcus aureus 
[38] 
- Lytic bacteriophages Bacteriophages (viruses which infect bacteria) have been 
demonstrated to be effective against biofilms through disruption 
of the EPS, and lysing of the biofilm-associated cells [39]. 
Removal of biofilms  
Debridement  
- Physical The biofilm, along with infected and non-infected tissue can be 
removed in a variety of ways.  
 Sharp debridement uses sharp blades to remove the 
infected plus healthy tissue [40].  
 Ultrasound (pulsed) and pulsed electrical fields can also 
be used to disrupt and remove biofilms, although these 
are not widely used [40]. 
- Chemical Three types of biofilm matrix degrading enzymes can be used to 
inhibit biofilm formation, and induce biofilm dispersion e.g. 
polysaccharide-degrading enzymes (such as alpha-amylase which 
has been shown to reduce cell aggregation in S. aureus biofilms 
[41], nucleases (e.g. DNase I), and proteases (which can inhibit 
biofilms by degrading the EPS, pili, fimbriae and surface adhesins 
[36]).   
Killing of biofilms 
- Systemic antibiotics Use of antimicrobial agents (often after debridement) to kill any 
remaining bacteria that would otherwise reform a biofilm.  - Topical antiseptics 
Table 1: Anti-biofilm strategies for wound care which aim to prevent, remove and/or kill 
biofilms (self-drawn) 
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1.3  Optimal treatment for wound/topical biofilms 
Systemic antibiotics are not optimal for treating wound biofilms owing to factors 
mentioned previously, combined with allergy, toxicity, and the development of resistance 
in non-target organisms. Therefore, wound biofilm management largely relies on the use of 
debridement followed by the application of topically applied biocides or antimicrobial 
agents. Debridement aims to physically disrupt the biofilm and reduce the biomass of 
bacteria down to small numbers, which then results in a 2-3 day window of time where the 
bacterial levels are low, and antibacterial agents may be more effective against the biofilm 
[42].  
Antimicrobial dressings (AMDs) account for a quarter of all dressings prescribed in primary 
care in England [43], and may contain a range of antimicrobial agents (e.g. silver, iodine, 
honey, and chlorhexidine). The use of AMD and silver-dressings (which are classed as 
‘advanced’ dressings) has risen in recent years, with £25 million spent on silver dressings in 
2006/7 [30]. Silver is a potent antimicrobial. Although silver-containing dressings vary in 
their composition, they act by a combination of i) absorbing wound exudates and killing the 
microorganisms drawn into the dressings, and/or ii) releasing active silver onto the wound 
bed. These biologically active ions then bind to negatively charged proteins, RNA, and DNA 
and damage bacterial cell walls, inhibit replication and reduce metabolism and growth [44].  
They are marketed as effective against a broad range of bacteria (growing as biofilms), and 
are indicated for a variety of wounds. Since they are considered to provide an ancillary 
action on the wound, they are classified as medical devices [45], and hence there are lesser 
requirements in terms of robust data to support safety and efficacy. A Cochrane Review 
from 2010 looking at the use of topical silver products (dressings and creams) for wound 
care, concluded that there was ‘insufficient evidence to support the use of silver containing 
dressings or creams, as generally they did not promote wound healing or prevent wound 
infections’ [46], and furthermore there is little data available in peer-reviewed literature 
[47]. Topical AMDs may also be associated with toxicity, bacterial resistance, and relative 
high cost. 
Biocides offer a possible alternative treatment and preventative measure for biofilm 
infections, and a number have been investigated in in vitro studies in this regard (including 
silver, (povidone) iodine, polyhexamethylene biguanide, ethylenediaminetetraacetic acid, 
octenidine and chlorhexidine). Generally they have broader spectrum activity and are less 
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selective in their actions than antibiotics [14,19], and therefore toxicity on host cells must 
be considered.   
 
1.4 The clinical need for alternative topically applied antimicrobial agents  
The body of work for this PhD was initiated by a Burns plastic surgeon based at the Queen 
Elizabeth Hospital, Birmingham (QEHB), who recognised in the course of daily clinical 
practice, that i) infection is a significant concern in patients who survive an initial burn 
insult (and accounts for over 75% of the mortality [48]), ii) burns patients are especially 
susceptible to infection owing to the injury removing the protective barrier provided by the 
skin, combined with general immunosuppression, the presence of endogenous microflora, 
prolonged hospital stays, and invasive diagnostic and therapeutic procedures, and iii), 
prevention and treatment of bacterial colonisation are key parts of burn wound care [47]. 
Despite the standard of care for such patients being the early excision of necrotic tissue, 
followed by the covering of the wound with an AMD, and administration of systemic 
antimicrobials (if infection is detected), there was some scepticism over the effectiveness 
of this strategy.  
Three topical antimicrobial agents (acetic acid, SurgihoneyRO, and blue light) have been 
investigated (in vitro) against key bacteria involved in burn and chronic wound infections. 
Although a diverse range of genera and species can be recovered from clinical biofilms, 
important pathogens include Gram-positive bacteria (e.g. S. aureus), and nosocomial Gram-
negatives (e.g. P. aeruginosa, Acinetobacter baumannii, Escherichia coli), most of which are 
often resistant to multiple drugs. 
Background information on these topical antimicrobial agents will be provided in 
subsequent sections.  
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2 AIMS & OBJECTIVES 
 
Despite the importance of biofilms to chronic wounds, the majority of in vitro testing that 
has been performed on antibiotics and antimicrobial wound care products has focussed on 
bacteria existing in the planktonic phase. Owing to the prevalence and recurrence of 
chronic wounds, and the recognition that biofilms are harder to treat than planktonic cells, 
biofilm testing of the novel topical agents was deemed of high importance.  
The aim of this work was firstly to evaluate the antibacterial activity of acetic acid (AA) 
against biofilms, following on from preliminary antimicrobial testing performed by Fraise et 
al. [49], and small-scale use of AA clinically on burns patients in QEHB. This led on to the 
testing of additional products (SurgihoneyRO (SH1) and blue light (BL)), for which no prior 
testing against biofilms had been performed.  
 
The specific objectives of the work were as follows: 
1. To test the in vitro antimicrobial activity of the agents against a large panel of 
clinically important nosocomial wound pathogens when growth is in the form of a 
biofilm.  
2. To compare the activity of one or more of the agents to conventionally used 
products 
 
This project focused on potential translation of these therapies and examination of activity, 
rather than examination of the mechanism of action of the agents. A mechanistic study of 
the three diverse classes of antimicrobial would be challenging and was considered beyond 
the scope of this work. 
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3 METHODS 
 
A series of simple, high-throughput in vitro experiments were conducted with a panel of 
organisms (Table 1, appendix 4) to determine the activity of the three topical test 
antimicrobial agents (TAA) against planktonic and biofilm growth. Not all assays were 
performed for each TAA, as detailed in Table 2 (appendix 4). 
 
The strains comprised well-characterised control strains and clinical isolates (including 
those from burn patients at QEHB), and were selected because of their relevance to 
infection in the burn unit setting (P. aeruginosa and A. baumannii), or their relevance as 
nosocomial wound pathogens (E. coli, Proteus mirabilis, S. aureus, Klebsiella pneumoniae 
and Enterobacter cloacae). Control strains were chosen to represent major globally 
relevant clonal complexes of the two species (ensuring the results are likely to be generally 
applied to each species as a whole), and also included control strains of S. aureus (NCTC 
10788, NCTC 12493) and P. aeruginosa (NCTC 6749, ATCC 27853), since these are 
recognised test strains in the EN standards for assessing the efficacy of chemical 
disinfectants (e.g. EN 13727 [50]). 
 
I tested diverse isolates (in preference to large numbers of related strains), and included 
recent isolates from burns patients to ensure no differences were seen in isolates from 
typical patient specimens. All P. aeruginosa and A. baumannii isolates were genotyped 
prior to the study through variable number tandem repeat analysis and pulsed-field gel 
electrophoresis, respectively by the relevant UK reference laboratories of Public Health 
England, to ensure that adequate levels of diversity were represented.  Isolates were 
stored at -80°C on Protect™ beads, and were routinely cultured on cysteine lactose 
electrolyte deficient (CLED) agar prior to each experiment. 
 
The in vitro assays were designed to test the antimicrobial activity of the TAA against 
planktonic bacteria in terms of the ‘minimum inhibitory concentration’ (MIC), and to assess 
whether the TAA could prevent the formation of a biofilm, and eradicate a pre-formed, 
mature biofilm. All assays involved the creation of an overnight bacterial culture, followed 
by quantification and dilution.  
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3.1 Preparation of Test Bacterial Inocula 
 
Fresh overnight Lysogeny Broth (LB) [Oxoid, Reading] cultures of the organisms were made 
by inoculating 3-5 colonies (off an 18-24 hour agar plate) into 5mls of sterile LB and 
incubating overnight at 37C with gentle agitation. The overnight cultures were then 
diluted in fresh antibiotic-free Iso-sensitest (ISO) broth [Oxoid] (for the MIC assay), or 
Muller-Hinton (MHB) broth [Oxoid] (for the biofilm assays), to an optical density (OD) at 
600nm (OD600) of 0.1. This will herein be referred to as the ‘test bacterial inoculum’ (TBI), 
and equates to approximately 105 colony-forming units per ml.  
 
 
3.2 Preparation of the Test Antimicrobial Agents 
 
3.2.1 Acetic Acid 
 
Acetic acid supplied at 5% w/v [Tayside Pharmaceuticals, Dundee, UK], was used as a stock 
for all experiments, and was diluted in sterile water to the following concentrations: 2.5%, 
1.25%, 0.63%, 0.5%, 0.4%, 0.31%, 0.16%, 0.1%, 0.09%, 0.08%, 0.06%, 0.05%, 0.04%, 0.03%, 
0.02%, and 0.01%. This range was chosen to reflect the concentration used in clinical 
practice (2.5%), and those below, so that the lowest effective concentration could be 
identified.  
 
3.2.2 Antimicrobial dressings (AMDs) 
 
A range of AMDs were prepared for testing by carefully cutting the sterile AMD into a 
number of 1cm2 pieces (sufficient for 1 piece per test well) using a sterile scalpel or a pair 
of ethanol-dipped flame sterilised scissors.  
 
 
3.2.3 SurgihoneyRO (SH1) 
 
SH1 and the other comparator honeys were diluted in sterile, autoclaved water to produce 
a range of test dilutions, since it was not possible to standardise the inoculum when they 
were neat. The strongest dilution was made by placing 6ml of honey into a universal tube 
and adding 14ml of sterile, autoclaved water to make a total volume of 20mls.  
 
NB: This was referred to in the paper as 1:3, but in hindsight this is misleading as this 
suggests 1 part honey to 3 parts water, when in reality it was 1 part honey to 
approximately 2 parts water. For clarity, this dilution should have been referred to as 1 in 3, 
 18 
 
or 1:2 relative to the honey component. I will use 1:2 from now on. Table 3 (Appendix 4) 
shows the ratios as published, and the revised ratios used in this thesis.  
 
The strongest dilution (1:2) was then serially double diluted down in water until 1:4096 was 
reached. Dilutions were made just prior to assay set up, to avoid any premature release of 
antimicrobial products from the honey.  
 
 
3.2.4 Blue light 
 
No preparation was needed for the blue light (BL) TAA. High-intensity 400nm BL was 
provided by a light-emitting diode (LED) flood array [Henkel-Loctite, Hemel Hempstead, UK] 
which gave a reproducible irradiance of 60mW/cm2  when the LED array was positioned 
15.5cm above the test area. The emission spectrum of the array was determined using a 
USB2000 spectrophotometer (Ocean Optics, Oxford, United Kingdom), and calibration was 
performed using a PM100D radiant power meter (Thorlabs, Newton, NJ).  
 
 
3.3 Planktonic MIC Assay  
 
Susceptibility of planktonic bacteria to the TAA was assessed by placing 50µl of the 
prepared TAA into wells of a 96-well microtiter tray (MTT), alongside 50µl of the TBI, and a 
further 50µl of ISO. Controls were included per assay, and comprised 50µl of the TBI 
alongside 100µl of ISO (for the positive control). The negative control comprised 150µl ISO 
alone (Figure 3). In line with the ESCMID-EUCAST guidelines of for the determination of 
MICs using a broth microdilution method [51], MTTs were incubated for 18-20 hours 
statically at 37°C, after which, the results were manually read. The MIC was recorded as the 
lowest concentration of the TAA for which growth was prevented.  
 
 
3.4 Biofilm ‘MBIC’ assay: preventing formation 
 
The impact of the TAAs on biofilm formation was assessed using a crystal violet (CV) biofilm 
formation assay, as described by Baugh et al. [52], with the endpoint measurement being 
the ‘minimum biofilm inhibitory concentration’ (MBIC). Wells of the MTT were loaded with 
100µl of the TBI, alongside either 100µl of TAA (for the test wells), or 100µl of sterile MHB 
(for the positive control wells), to a total volume of 200µl. Negative controls were included, 
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comprising of 200µl MHB only. MTTs were sealed and incubated statically for 72 hours at 
33°C (the average temperature of the surface of a wound [53]) (Figure 4).  
 
3.4.1 MBIC CV assay 
 
After 72 hours, the liquid was removed from the wells, and the MTTs rinsed in tap water to 
remove any unbound cells. Any existing biofilms were then visualised through staining with 
200µl of 1% CV [Sigma Aldrich, Poole], further rinsed (as above) to remove unbound CV, 
and dye solubilised by the addition of 200µl of 70% ethanol. The OD600 of the solubilised CV 
solution was then measured with a FLUOstar Optima [BMG Labtech] to assess the biomass 
of the biofilms.   
 
The positive and negative controls for each test MTT were examined and if within a normal 
range, the rest of the data were analysed for statistical significance by comparing values for 
the TAA treated wells to the untreated (control) wells, using the Student’s ‘t’ test.  
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Figure 3: Flow diagram showing the stages involved in the minimum inhibitory concentration (MIC) assay 
50µl each of bacterial inoculum (isolate in broth), diluted TAA, and ISO broth were added to wells of a 96 well MTT, alongside a negative, and a positive control (for composition, see * 
in figure). The MIC was manually read after 18 hours of incubation. [Diagram and photo candidate’s own].  
 
20 
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Figure 4: Flow diagram showing the stages involved in the minimum biofilm inhibition concentration (MBIC) assay 
100µl of bacterial inoculum (isolate in broth), was added to an equal volume of the diluted TAA in a 96 well MTT, alongside a negative, and a positive control (for composition, see * in figure). 
Assessment of biofilm formation was performed using a crystal violet assay, resulting in an ethanol-solubilised crystal violet solution that was measured in terms of optical density [Diagram 
and photo candidate’s own].  
21 
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3.5  Biofilm ‘MBEC’ assay: eradication of pre-formed biofilms 
 
The antibacterial activity of the TAAs against pre-formed biofilms was assessed by 
conducting ‘minimum biofilm eradication concentration’ (MBEC) experiments per isolate, 
as per Ceri et al. [54]. To produce a ‘transferable’ mature biofilm, 200µl of the TBI were 
loaded into wells of a MTT, and a 96 well polypropylene plate [Starlabs, UK] placed into the 
MTT, so that each well contained a ‘peg’ on which biofilms could form. Once positive and 
negative control wells were included, the assembly was sealed with cling film, and statically 
incubated at 33°C (the average temperature of the surface of a wound [53]) for 72 hours 
(Figure 5).  
 
After this time, the pegs were washed in a MTT containing sterile water (to remove any 
unbound cells), and the peg plate then placed either into a further MTT containing the TAA 
(AA or SH1) at a range of concentrations, or underneath the BL LED light array. The 
exposure time differed per TAA (and was arbitrarily chosen), with pegs exposed to AA for 3 
hours, SH1 for 24 hours, and BL for 1 hour maximum (15 minute intervals).  
 
To assess the viability of the exposed peg biofilm, the peg plate was removed from the TAA, 
washed as before and placed into a MTT containing 200µl sterile ‘reporter’ broth (MHB) for 
overnight incubation. After 18 hours, the OD of the reporter broth was measured to assess 
the viability (seeding) of the biofilms following the exposure to the TAA, and to determine 
the minimum concentration which prevented any seeding of the reporter broth (and by 
inference had killed some of the cells in the biofilm).  
 
3.5.1 MBEC CV assay 
 
To demonstrate the presence of biofilms on the pegs, CV assays were performed on the 
pegs after the OD of the reporter broth had been measured. This involved placing the pegs 
into MTTs containing 200µl of 1% CV, followed by washing and subsequent solubilisation in 
200µl of 70% ethanol.  
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Figure 5: Flow diagram showing the stages involved in the minimum biofilm eradication concentration (MBEC) assay 
200µl of bacterial inoculum (isolate in broth), was added to wells of a 96 well MTT, alongside a negative, and a positive control (for 
composition, see * in figure). A peg plate was then added and incubated for 72 hours at 33°C so that ‘transferable’ biofilms were formed. 
Biofilms were then exposed to the TAA, and the viability (seeding) of the exposed biofilms was assessed. As a final stage, a crystal violet assay 
was performed to determine whether biofilms had been present on the exposed test pegs.  [Diagram and photo: candidate’s own]. 
23 
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3.6  Polymicrobial biofilm assays 
 
To investigate the antimicrobial activity of the TAAs on polymicrobial biofilms, a small 
number of MBEC experiments were performed using AA, and two Gram-positive (S. aureus 
and Enterococcus faecium), and two Gram-negative (P. aeruginosa and A. baumannii) 
isolates. These bacterial species were selected owing to their easily-distinguishable colony 
morphologies, which made it possible to identify which bacteria were present by visual 
inspection, and without the need for any identification tests.  
To make a polymicrobial biofilm, I initially added equal volumes (50µl) of both the Gram-
positive and Gram-negative bacteria to the MTT (with 96 well polypropylene plate 
inserted), at the same time, at the start of the experiment. The composition of the biofilm 
was assessed (through plating on solid agar) after 72 hours, and demonstrated that the 
Gram-negative bacteria had completely outcompeted the Gram-positive.  
Following a literature search, a new protocol was devised. This loosely followed that of 
Guggenheim et al. [48], and involved growing pure and mixed Gram-positive biofilms on 
peg plates for 41.5 hours, before adding in the Gram-negative bacteria and incubating for a 
further 23 hours, so that the peg plates contained polymicrobial biofilms. The mature 
biofilms (64.5 hours old) were then exposed to AA for 3 hours, before the viability of the 
exposed biofilm was assessed (as per 3.5).  
To confirm the existence of a polymicrobial biofilm, serial dilutions of the seeded reporter 
broth were plated out onto standard blood agar and colonies inspected. 
 
3.7 Data analysis 
All experiments were repeated on separate occasions and at least two biological and three 
technical replicates were used (per concentration) to ensure reproducible data sets were 
obtained. Data analysis was performed as detailed in the individual published papers. In 
general the positive and negative controls were examined and if within a normal range 
(according to OD readings), the rest of the data were analysed for statistical significance by 
comparing values at each concentration of TAA to untreated (positive) controls using the 
Student’s ‘t’ test.  
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4 SUMMARY OF THE PUBLISHED WORKS 
 
4.1 Investigation of the antibacterial activity of acetic acid (paper 1) 
This paper investigated the antibacterial activity of acetic acid (AA), against 29 clinical and 
control bacterial isolates (growing both planktonically and in biofilms) of relevance to the 
nosocomial setting (e.g. the QEHB Burns Unit). This was prompted by initial observations 
on the antibacterial planktonic activity of AA as reported by Fraise et al. [49], and through a 
QEHB Burns plastic surgeon who had observed AA (of concentration 2.5% w/v), to be well-
tolerated, and have good clinical outcomes when applied topically within dressings to 
patients with heavily colonised wounds. This work was further justified by the paucity of 
literature surrounding the antibacterial activity of AA.  
AA, or vinegar, has been used sporadically in medicine for 6000 years [55,56], with 
evidence of successful elimination of P. aeruginosa from war wounds [57], and treatment 
of the plague, and ear, chest, and urinary tract infections [58–60]. Historically, several 
small-scale studies have been performed which have shown effectiveness of AA against 
wound infection [55,56,61,62].  Sloss et al. [61] recruited 16 patients with P. aeruginosa-
infected burns or ulcers, and treated them with sterile gauze soaked in 1-5% AA, applied for 
15 minutes twice daily, for 14 days. Over the study period, swabs were taken to assess the 
elimination of organisms from the wounds, and the MIC of AA needed to inhibit the growth 
of each isolate. Of 16 patients, P. aeruginosa was eliminated from ten within seven days 
and from five more within 14 days.  
Ryssel et al. [55] assessed the activity of 3% AA against a range of Gram-negative and 
Gram-positive bacterial strains isolated from patients in their Burns Unit. Overnight 
cultures of the organisms were exposed to 3% AA for 5, 30, and 60 minutes at 37°C before 
being diluted and covered with agar. After 48 hours incubation, the numbers of colony-
forming units were counted, and analysis revealed good activity of AA, with the majority of 
the organisms (Proteus vulgaris, P. aeruginosa, A. baumannii, ß-haemolytic Streptococci A 
and B, S. epidermidis, S. aureus, and Enterococcus faecalis) eradicated after just 30 minutes 
of exposure. Furthermore Madhusudhan [63] tested the efficacy of 1% AA for the 
treatment of chronic wounds infected with P. aeruginosa. Thirty two patients were 
enrolled and randomised to receive twice daily dressing changes with AA or saline. P. 
aeruginosa was eliminated seven days earlier with AA treatment compared to saline.  
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A recent paper by Bjarnsholt et al. [64] tested the in vitro ability of 0.5% or 1% AA to 
eradicate pre-existing biofilms of P. aeruginosa or S. aureus during 24 hour exposures. They 
found that P. aeruginosa biofilms were completely eradicated by 0.5% AA, but S. aureus 
required the higher dose of 1% AA for complete eradication.  
Although these clinical studies provide evidence in support of the clinical utility of AA, the 
small sample sizes, heterogenous nature of the studies, and majority focus on planktonic 
growth, make it difficult to draw conclusions.  The current study was undertaken to further 
investigate the in vitro antibacterial activity of AA against important burn wound colonising 
organisms growing planktonically and as sessile biofilms.   
Experiments measured the MIC, MBIC and MBEC of AA (at concentrations from 5% to 
0.01%), and the results were highly reproducible. AA was antibacterial against planktonic 
growth, with an MIC of 0.16% (9 isolates) or 0.31% (20 isolates). The difference in MIC for 
different strains of the same species was not considered significant, and was not linked to 
any differences in antibiogram.  
In terms of biofilms, AA was able to prevent formation of biofilms (at all concentrations 
from 5% down to 0.31%) for the 23 isolates tested (6 isolates were omitted due to poor or 
unreliable biofilm formation in the control wells). Five organisms had MBICs of <0.10%, 10 
of 0.16%, and the remaining eight had MBICs of 0.31% (Table 2). There was no observable 
pattern between MBICs and species of bacteria, with isolates of P. aeruginosa with a 
variety of MBICs. Reduced seeding of mature biofilms was observed for all 22 isolates 
(seven isolates were not tested as they were unreliable biofilm producers) after 3 hours of 
exposure. The MBECs of AA ranged from ≤0.10% to 2.5%, and for 11 isolates, there was 
statistically significant reduction in seeding at all dilutions of AA.  
Example graphs are shown for the MBIC and MBEC results in Figures 6 and 7, respectively.  
This work has revealed that AA is antibacterial against a wide range of bacterial species, 
and is active at a far lower concentration than currently used at the hospital, and those 
previously reported in the clinical trials. This adds a lot of information to the AA story, since 
such comprehensive testing has not been done before, and previous authors were using far 
higher concentrations of AA (e.g. 2-5%). Based on these data, I feel these high 
concentrations are unnecessary and could prove to be uncomfortable to patients. Owing to 
current concerns of the reducing efficacy of systemic antibiotics, AA therefore offers great 
promise as a cheap and effective measure to treat infections in burns patients.  
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Table 2: showing the results for the tests performed on the 29 isolates in terms of 
minimum inhibitory concentration (MIC), minimum biofilm inhibition concentration (MBIC) 
and minimum biofilm eradication concentration (MBEC) of acetic acid (AA).  
 
The numbers in brackets refer to the inhibitory % of AA (in terms of weight/volume), and the tick symbol 
denotes that the test was performed and the result. All results derive from 12 technical replicates per isolate 
and per dilution of AA. The superscript b denotes that there was statistically significant reductions in seeding at 
all concentrations of AA (according to a Student’s t-test with n-1 degrees of freedom) 
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Figure 6: Graph showing the mean average biomass of the biofilms produced by isolates of P. aeruginosa (PS_PA01), A. baumannii 
(AB_19606), K. pneumoniae (MDR_A), and S. aureus (MSSA_10788) when planktonic cells were incubated with a range of dilutions of 
acetic acid for 72 hours. Optical density (OD) on the y axis refers to the average biofilm biomass for the isolates when tested against the range of AA dilutions shown on the x axis. Each 
data bar represents the mean average biofilm biomass from 12 technical replicates. Standard error bars have been included, alongside asterisks (*) which denote statistically significant 
reductions in biofilm biomass according to the Student’s t–test with n-1 degrees of freedom, and a significance threshold of 0.05. The positive control represents the average biomass of biofilm 
produced in the absence of acetic acid. The negative control (composed of broth only) represents the background OD levels for the experiment.  
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Figure 7: Graph showing the mean average biofilm seeding results when 72 hour old 
biofilms produced by PS_PA01, AB_19606, MDR_A (A) and MSSA_10788 (B) were 
exposed to dilutions of acetic acid (AA) for 3 hours. Biofilm seeding is shown on the y axis for the isolates at 
the range of AA dilutions tested (x axis). Each data bar represents the mean average biofilm seeding from 12 technical replicates. Standard 
error bars have been included, alongside asterisks (*) which denote statistically significant reductions in biofilm seeding (compared to the 
positive control) according to the Student’s t–test with n-1 degrees of freedom, and a significance threshold of 0.05. OD: Optical density, 
PS_PA01: Pseudomonas aeruginosa, AB_19606: Acinetobacter baumannii, MDR_A: Klebsiella pneumoniae, MSSA_10788: Staphylococcus 
aureus.  
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4.2 Comparison of the ability of a panel of antimicrobial dressings (AMDs) to prevent 
biofilm formation (paper 2) 
 
The NHS spent £110 million (in 2014-2015) on advanced wound dressings and antimicrobial 
dressings (AMDs) [65]. Although AMDs may contain a range of different antimicrobial 
agents (e.g. silver, iodine, honey, and chlorhexidine), the majority prescribed in England 
contain silver. Typically the antimicrobial agent is contained within a commercially 
marketed wound dressing, which may be used prophylactically (to prevent colonisation of 
the wound and subsequent biofilm formation), and in the treatment of established 
infection [66]. This paper compared the ability of a range of 11 AMDs to prevent biofilm 
formation of four important burn wound pathogens. It was prompted from the work 
conducted on AA, since it was necessary to demonstrate (as part of an undergraduate 
placement-year project), how AA compared in terms of antimicrobial activity, to the 
standard of care (SOC) treatments used in the Burns Unit at QEHB.  
AMDs are used heavily for burns patients, where infection is a large risk, where prevention 
and treatment of bacterial colonisation are key parts of wound care, and where systemic 
antimicrobials are not thought to be effective [26,30,67]. They are marketed as broad-
spectrum antimicrobials; effective against both Gram-positive and Gram-negative bacteria 
[68] growing as biofilms, as well as viruses [69], and fungi [70]. However, provided that the 
antimicrobial agent only provides an ancillary action on the wound, the majority of AMDs 
are classified as medical devices [45]. This means that there are lesser requirements for 
robust data (e.g. from randomised controlled trials (RCTs)), and literature reviews and 
commercial company-led research are often deemed acceptable for licensing. 
Consequently, there is little data available in peer-reviewed literature concerning their 
activity. Opinions on silver dressings are divided in clinical practice, with some clinicians 
believing them to have a role in preventing infection in burns patients [71–73], and others 
not endorsing their use owing to a lack of evidence of effectiveness [30,74], and a non-
supportive Cochrane Review [75].  
I sought to assess and compare the antibiofilm properties of AA versus a representative 
selection of the AMDs currently used in the Burns Unit at QEHB, with the aim to help guide 
clinical practice at this centre and others. 
Four organisms were tested (two A. baumannii and two P. aeruginosa) against 11 AMDs 
and two non-antimicrobial dressings (nAMDs). Here the MBIC assay was performed, with 
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slight modifications; 24 well MTTs were used, and were filled with a total of 2ml of liquid 
(1ml TBI plus 1ml AA (as comparator), or 1ml water (AMD test wells)). Additionally, the 
AMD test wells contained 1cm2 pieces of the 11 AMDs and two nAMDs (dressing volumes 
were not considered). The MTTs were sealed, and statically incubated at 33°C for 72 hours. 
Experiments were performed using at least two biological replicates, and at least four 
technical replicates of each isolate.  
The CV assay was performed (scaling up to 2mls), and the data analysed in terms of the 
percentage change in biofilm biomass between the test wells (containing the TAA), and the 
(untreated) positive control wells. The results are shown for the A. baumannii isolates 
(Table 3 and Figure 8). The Student’s t-test was used to compare the percentage changes, 
and adjustments for multiple comparisons were made (to control for the family-wise error 
rate) using Holm’s method [76] to obtain a p-value of statistical significance.  
This study was not designed to demonstrate shortcomings in the performance of the 
AMDs. However, the data indicates that (in this experiment and in the in vitro setting) there 
is a large variation between the AMDs in terms of reducing/preventing biofilm formation. 
This is apparent between dressings containing the same antimicrobial agent (e.g. silver), 
and those containing different AM agents. For the seven silver AMDs, Mepilex®Ag, and 
Acticoat were highly effective, leading to 90-100% reductions in biofilm formation, 
compared to the Aquacel® dressings, where the reductions were modest, averaging 44% 
for PS_PA01, and 34% for PS_1586. The four non-silver AMDs gave varied results (Table 3), 
and in some cases were ineffective at preventing biofilm formation (e.g. biofilm formation 
of PS_PA01 and PS_1586 was increased compared to the positive control by 115 and 200% 
with L-Mesitran® Hydro, respectively). In contrast, the AA results were consistent, showing 
reductions of >90% for all concentrations of AA and for all isolates and replicates.  
This work demonstrates that the antibacterial activity of AA compares favourably to the 
best-performing AMDs, and that clinicians should be wary using of AMDs (if intended to 
prevent or treat infections) in the absence of robust data showing anti-biofilm efficacy.  
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Dressing/agent 
A. baumannii ACI_AYE  A. baumannii ACI_721 
Percentage 
change 
Number of 
replicates 
Adjusted  
p-value 
Percentage 
change 
Number of 
replicates 
Adjusted  
p-value 
AMD (silver) Mepilex® Ag -95.9 8 0.001 -100 6 <0.001 
Aquacel® Ag -39 8 1.000 -74 6 0.006 
Aquacel® Ag Foam -66 8 0.295 -74 6 0.010 
Aquacel® Ag Burn -94 6 0.031 -82 4 0.032 
UrgoTul® Silver -20 10 1.000 -4 8 1.000 
Acticoat -96 8 0.002 -100 6 <0.001 
PolyMem Silver® -61 8 0.090 -75 6 0.001 
AMD (iodine) Inadine® +3 8 1.000 -6 6 1.000 
AMD (honey) L-Mesitran® Net -10.4 6 1.000 +33 4 0.385 
L-Mesitran® Hydro -1 8 1.000 -62 6 0.038 
AMD (chlorhexidine) Bactigras -59 8 0.148 -68 6 0.038 
nAMD UrgoTul® plain -7 6 1.000 -27 4 0.405 
PolyMem®  plain -66 6 0.054 -74 4 0.003 
AA Acetic acid 5% -92 10 <0.001 -90 8 <0.001 
Acetic acid 2.5% -93 10 0.001 -92 8 <0.001 
Acetic acid 1.25% -93 10 <0.001 -93 8 <0.001 
Acetic acid 0.63% -93 10 <0.001 -96 8 <0.001 
Acetic acid 0.31% -93 10 <0.001 -96 8 <0.001 
Acetic acid 0.16% -90 10 0.001 -94 8 <0.001 
Acetic acid 0.08% -28 10 1.000 -95 8 <0.001 
Acetic acid 0.04% +10 10 1.000 +5 8 1.000 
Acetic acid 0.02% +6 10 1.000 +13 8 0.787 
Acetic acid 0.01% -30 4 1.000 +7 4 1.000 
The number of replicates, and the p-values from the Student’s t-test (performed with n-1 degrees of freedom and adjusted for multiple comparisons using Holm’s method) are also shown. 
Negative values (denoted by -) in the ‘percentage change’ column denote reductions in biofilm biomass compared to the untreated positive control. Positive values (denoted by +) denote 
increases in biofilm biomass compared to the untreated positive control.  
 
Table 3: Average percentage (%) change in biofilm biomass for each of the A. baumannii isolates (ACI_AYE and ACI_721) when planktonic 
cells were coincubated with each of the antimicrobial dressings (AMDs), non-antimicrobial dressings (nAMDs), or acetic acid (AA) for 72 
hours, when compared to an untreated (positive) control. 
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Figure 8: Graph showing the mean average biomass of the biofilms produced by the two A. baumannii isolates that were produced 
when planktonic cells were incubated a range of antimicrobial dressings, non-antimicrobial dressings, or acetic acid for 72 hours. 
Optical density (OD) on the y axis refers to the average biofilm biomass for the A.baumannii isolates when tested against the range of agents shown on the x axis.  Each 
data bar represents the mean average biofilm biomass from 4-10 technical replicates (see Table 3), and standard error bars have been included. The positive control 
represents the average biomass of biofilm produced in the absence of any of the test agent. The negative control (which has been subtracted) provides a baseline OD 
value for the assay in the absence of bacteria or test agents.  
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4.3 Investigation of the antibacterial activity of an engineered honey, medical-grade 
honeys, and antimicrobial wound dressings (paper 3) 
 
SH1 is a newly licensed sterile product which has been developed for wound care, and as a 
prophylactic dressing agent (Figures 9A & B). It has been engineered so that it produces 
consistently high levels of reactive oxygen species (ROS), and consequently is thought to 
have enhanced antimicrobial activity compared to other medical honeys. This in vitro study 
was performed to assess whether SH1 has antibacterial activity against biofilms, in terms of 
preventing formation. Direct comparisons were also made to competitor honeys and honey 
and silver-based dressings.  
  
Figure 9A: Composite figure: SurgihoneyRO. 1: SurgihoneyRO sachets (as used in 
the experiments) and other formulations, 2: Neat SurgihoneyRO, 3: H2O2 negative 
reaction of MH (left) and positive reaction of SH1 (right) (all self-taken).  
1 
2 3 
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Honey has a long history as a wound care agent. In addition to wound healing properties 
[77], honey has broad spectrum antibacterial activity, with 37 genera of bacteria shown to 
be susceptible [78–80], and a multifactorial mechanism of action.  The antimicrobial 
components of the honey are thought to be the preparation itself (e.g. the physical 
properties including pH and hyperosmolarity), and innate antibacterial compounds 
including methylglyoxal, bee defensin-1, and ROS such as hydrogen peroxide (H2O2) [81].  
A limitation of natural honeys is that the production depends on a large number of factors 
(e.g. floral source, species of bee, geographical location, harvesting process, and 
subsequent storage conditions) [81], and consequently the honey may not be of 
predictable and consistent quality. Medical honeys are generally standardised in 
preparation.  
SH1 differs from medical honey, in that it has enhanced production of ROS, does not 
require a single floral source, and can be scaled up or down in terms of potency [82]. Pilot 
in vitro tests performed by Dryden et al. [82] measured the antimicrobial activity against 48 
Gram-positive and Gram-negative bacterial isolates using an agar diffusion method. Zones 
of inhibition around the honey preparation were observed after 18-24 hours incubation, 
and SH1 formulations had larger zones of inhibition (and therefore higher antibacterial 
activity) than the other honeys tested. Clinical results (using SH1 topically) have also been 
favourable [83].  
Figure 9B: SurgihoneyRO: proposed mechanism of action of SurgihoneyRO (self-drawn) 
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Sixteen bacterial isolates were tested using the MBIC assay against three medical honeys 
(SH1, Medihoney® (Med), and Activon® tube 100% medical grade Manuka honey (MH)), 
and a subset then tested against the five AMDs. Three of the AMDs were honey-containing 
(Actilite®, L-Mesitran® Net, and L-Mesitran® Hydro), and were chosen from a number of 
honey dressings used at QEHB to act as comparators. The silver dressings (Aquacel® Ag and 
Aquacel® Ag+) were included since they represent the most commonly used dressings in 
the Burns Unit.  
The MBIC was performed as previously, with the MBIC defined as the lowest dilution of 
honey where there was both statistical significance in the t-test (p<0.05), and a prevention 
of biofilm biomass accumulation ≥50% compared to the positive control.  
All honeys were antibacterial and able to prevent biofilm formation, but SH1 was the most 
potent, with MBIC values ranging from 1:4 to 1:128 (Table 4), and potency at lower 
dilutions than both of the other honeys for five isolates; and equivalent dilutions for a 
further six. For the remaining isolates, SH1 was either the only effective honey (PS_PA01), 
was one of two effective honeys, or gave discordant/concordant results compared with the 
other honeys. MH prevented biofilm formation for 14 of the 16 isolates, but was repeatedly 
ineffective for two isolates, with no statistically significant reduction in biofilm biomass 
even at the strongest concentration. Similarly, Med was effective for 15 of the 16 isolates 
(ineffective for PS_PA01), and had MBICs ranging from 1:2 to 1:1024. Sample data is shown 
in figure 10. 
Four of the P. aeruginosa isolates were additionally tested against SH1 (chosen owing to 
the higher potency1) and the AMDs. Percentage change in biofilm biomass was calculated 
for all the results (since MBIC values were not possible for the AMDs) (Table 5). There was a 
large variation in the ability of the test agents to prevent biofilm formation (Figure 11). SH1 
(at a dilution of 1:2) was effective for all isolates, leading to significant reductions ranging 
from 79.8% (PS_1586) to 94.1% (PS_PA01). These results furthermore compared favourably 
with the reductions observed with the silver dressings. The performance of the honey-
containing dressings was disappointing, with increases in biofilm biomass seen with all 
dressings for three of the isolates, and an increase of 62.3% seen with Actilite® and 
PS_PA01.  
 
                                                          
1 And since it was not logistically possible to test all honeys  
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This study has demonstrated that the medical honeys tested were effective at reducing 
biofilm formation in this in vitro model, and that SH1 was superior in potency. Additionally, 
it has shown that a number of honey dressings currently marketed as being antimicrobial, 
have poor levels of antimicrobial activity in vitro. These findings have furthermore informed 
a translational clinical trial being undertaken at QEHB into the use of SH1 for the treatment 
of chronic, non-healing ulcers.  
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Table 4: Showing the minimum biofilm inhibition concentration (MBIC) data for each of 
three honeys (SH1, MH and Med) and for the 16 isolates included in the study 
 
Abbreviations: MBIC – Minimum biofilm inhibition concentration, SH1 – SurgihoneyRO, MH – Manuka Honey,                   
Med – Medihoney.  
Symbols: * MH or Med MBIC equivalent to the SH1 MBIC, ¤ MH or Med MBIC is a stronger dilution of honey 
than SH1, ^ MBIC for MH or Med is a weaker dilution of honey than SH1.  
The sample size (n), and the p-values from the Student’s t-test (performed with n-1 degrees of freedom) are 
also shown.  
 
 
 
 
 
 
 
Isolate SH1 MH Med 
MBIC 
 
n p-value MBIC N p-value MBIC n p-value 
PS_PA01 
 
1:4 6 <0.001 >1:2 n/a n/a None n/a n/a 
PS_1054 
 
1:8 6 <0.001 1:8 * 6 <0.001 1:8 * 6 <0.001 
PS_1586 
 
1:4 6 <0.001 1:2 ¤ 6 0.02 1:8 ^ 6 0.019 
PS_6749 
 
1:8 6 <0.001 1:8 * 6 <0.001 1:1024^ 6 0.009 
ACI_AYE 
 
1:8 6 <0.001 1:8 * 6 <0.001 1:2 ¤ 6 <0.001 
ACI_C59 
 
1:8 6 <0.001 1:2 ¤ 6 <0.001 1:2 ¤ 6 <0.001 
ACI_C60 
 
1:8 6 <0.001 1:2 ¤ 6 <0.001 1:2 ¤ 6 <0.001 
ACI_19606 
 
1:8 6 <0.001 1:4 ¤ 6 <0.001 1:4 ¤ 6 <0.001 
MDR_B 
 
1:32 6 <0.001 1:4 ¤ 6 <0.001 1:16 ¤ 6 <0.001 
MDR_C 
 
1:128 6 <0.001 1:128 * 6 <0.001 1:128 * 6 <0.001 
MDR_D 
 
1:16 6 <0.001 1:2 ¤ 6 0.023 1:2 ¤ 6 0.043 
EC_042 
 
1:64 6 <0.001 1:64 * 6 <0.001 1:64 * 6 <0.001 
MRSA_F475 
 
1:32 6 0.04 None n/a n/a 1:16 ¤ 6 0.036 
MSSA_10788 
 
1:16 6 0.04 1:16 * 6 0.001 1:16 * 6 <0.001 
MRSA_F483 
 
1:128 6 <0.001 1:128 * 6 <0.001 1:128 * 6 <0.001 
MSSA_F77 
 
1:32 6 <0.001 1:32 * 6 0.006 1:32 * 6 0.02 
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Table 5: Table showing the average percentage (%) change in biofilm biomass for each of 
the Pseudomonas aeruginosa isolates when coincubated with SH1 and each of the 
antimicrobial dressings for 72 hours, when compared to an untreated, positive control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: % change values refer to the percentage increase (denoted by +), or decrease (denoted by -) in biofilm 
biomass for the P.aeruginosa isolates treated with the dressings or SH1, compared to an untreated positive 
control. SH1: SurgihoneyRO, n: number of replicates, T-test p-values: values obtained from the Student’s t-test 
performed between treated and untreated data points with n-1 degrees of freedom.  
 
 
 
 
 
 
 
 
Dressing/agent 
P. aeruginosa PS_PA01 P. aeruginosa PS_1054 
%  change n T-test 
p-value 
%  change n T-test 
p-value 
Aquacel® Ag 
 
-38.4 3 0.33 -94.1 2 0.001 
Aquacel® Ag + Extra 
 
-95.3 4 0.007 -86.8 4 <0.001 
Actilite 
 
+62.3 4 0.063 +87.2 4 0.048 
L-Mesitran® Net 
 
-27.8 4 0.132 +129.7 4 0.047 
L-Mesitran® Hydro 
 
-15.8 4 0.488 +43.1 4 0.431 
SH1 1:2 
 
-94.1 6 0.005 -86.7 6 0.01 
SH1 1:4 
 
-82.8 6 0.01 -76.6 6 0.029 
SH1 1:8 
 
-34.9 6 0.16 -57.08 6 0.005 
SH1 1:16 
 
+22 6 0.25 +7.5 6 0.02 
SH1 1:32 
 
+4.5 6 0.81 +22 6 0.12 
SH1 1:64 
 
-1.6 6 0.93 +9.7 6 0.37 
SH1 1:128 
 
-32.1 6 0.68 -25.4 6 0.5 
SH1 1:256 
 
-34.2 6 0.184 -25.5 6 0.29 
SH1 1:512 
 
-19.6 6 0.39 -14.2 6 0.64 
SH1 1:1024 
 
-11.4 6 0.58 +6.03 6 0.67 
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Figure 10: The mean average biomass of the biofilms of P. aeruginosa isolate PS_PA01 
(A), and ESBL positive E. coli  MDR_C (B) that were produced when planktonic cells were 
incubated with three types of honey (SH1, MH and Med) for 72 hours. Optical density (OD) on 
the y-axis refers to the average biofilm biomass for the isolate and the range of honey dilutions tested. Each data bar 
represents the mean average biofilm biomass from 6 technical replicates. The standard error of the mean is also plotted. POS 
(ave) is the positive control and represents the average biomass of biofilm produced in the absence of honey. NEG (ave) is the 
negative control. 
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Figure 11: Graph showing the mean average biomass of the biofilms produced by the four P. aeruginosa isolates that were produced when planktonic 
cells were incubated with five different antimicrobial dressings (AMDs) or Surgihoney (SH1) for 72 hours. Optical density on the y axis refers to the average biofilm 
biomass for the P. aeruginosa isolates when tested against the range of agents shown on the x axis.  Each data bar represents the mean average biofilm biomass from four technical 
replicates (for the AMDs) and from six replicates for the SH1 dilutions. Standard error bars have been included, alongside asterisks (*) which denote statistically significant reductions in 
biofilm biomass according to the Student’s t–test with n-1 degrees of freedom, and a significance threshold of 0.05. POS (ave) is the positive control and represents the average biomass of 
biofilm produced in the absence of any test agent. NEG (ave) is the negative control. 
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4.4 Investigation of the antibacterial activity of blue light against nosocomial wound 
pathogens (paper 4) 
 
The blue wavelengths (400-470nm) within the visible light spectrum are intrinsically 
antimicrobial, and can photodynamically inactivate the cells of a wide spectrum of Gram-
positive and Gram-negative bacteria, as well as fungi [84,85]. This occurs due to 
photoexcitation of intracellular porphyrins [86], which leads to energy transfer, and the 
production of cytotoxic ROS (e.g. singlet oxygen) [87–89] (Figure 12). Maximum porphyrin 
absorption occurs at 405nm [90], and successful inactivation (and killing) by blue light (BL) 
has been demonstrated at this wavelength in vitro against a range of nosocomial 
pathogens [91–93]. Furthermore, BL therapy has been shown to significantly reduce the 
bacterial burden of wounds infected with P. aeruginosa [94], MRSA [95], and A. baumannii 
[96].  
Currently BL is used topically to treat acne vulgaris [97], and internally as a ‘light string’ to 
treat Helicobacter pylori [98]. It has also been incorporated into a hospital disinfection 
strategy called the HINS-light environmental decontamination system [86,99], which 
delivers BL constantly (as part of a light fitting), and is suitable for patient occupied 
settings. Evaluation studies have shown that this can reduce numbers of cultivable 
Staphylococci spp. on surfaces by 90% when used for 24 hours in an unoccupied room 
[100], and by 56-86% when used in rooms occupied by MRSA positive patients.  
I sought to investigate the antibacterial activity of BL against mature biofilms formed by 
nosocomial wound pathogens. This was warranted since the majority of research on BL has 
involved bacteria in the planktonic phase, and for treating or preventing wound infections 
it is necessary to demonstrate anti-biofilm activity.  
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1 2 
3 4 
Figure 12: Composite figure: Blue light. 1; the electromagnetic spectrum at 400-700nm 
(google images), 2; biofilms on pegs being exposed to blue light (own photo), 3; basic 
porphyrin structure (google images), 4; mechanism of action of blue light showing damage 
(indicated by red X) to DNA, cell membranes and components within the cell  (J Thwaite –
Dstl collaborator) 
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Experiments were performed on 34 bacterial isolates in both planktonic and biofilm modes 
of growth. The panel comprised a range of control and clinical isolates, but mostly focussed 
on A. baumannii owing to their importance as nosocomial pathogens, the high levels of 
antimicrobial resistance, and their relevance to the QEHB setting (a large protracted 
outbreak had occurred involving 65 patients from July 2011 to February 2013). All 
planktonic-phase bacteria were susceptible to BL treatment, with the majority (71%) 
demonstrating ≥5 log10 decrease in viability after 15-30 minutes exposure (54 J/cm2 to 108 
J/cm2). This testing was performed by a collaborator at Dstl (Defence Science and 
Technology Laboratory), and will not be mentioned further. 
The MBEC assay was performed on 72 hour mature biofilms by placing peg-plates 
(containing the biofilms) under the BL LED array for 15, 30, 45 and 1 hour timepoints (this 
corresponded to BL doses of 54, 108, 162 and 216 J/cm2, respectively). A positive and 
negative control plate, covered in foil and placed under the array, was included per 
timepoint in order to control for any impacts of heating or drying on the viability of the 
biofilms. After exposure, the peg-plates were placed into reporter broth, and the 
viability/seeding of the biofilms assessed after 18 hours incubation.  
BL treatment resulted in reductions in biofilm seeding for all isolates tested (Figure 13), and 
reductions were statistically significant (p<0.05) for all except one isolate at one timepoint 
(MSSA_10788 at 15 minutes). The Gram-negative isolates were the most susceptible, with 
>80% reductions in biofilm seeding for 11/28 isolates after 15 minutes, rising to 26/28 
isolates at 60 minutes (Table 6). Interestingly, the Gram-positive isolates were less 
susceptible to BL treatment (literature states that Gram positive organisms are generally 
more susceptible than Gram negative [84]), with only two isolates (33%) achieving at least 
90% reductions in biofilm seeding at 60 minutes. However, this may be an artefact of the 
small sample size. There were two particularly interesting results which were repeatable 
and were seen in a number of replicates. One of the Enterobacter cloacae isolates 
(ENTCL_804) responded well to BL treatment with reductions at 30, 45 and 60 mins (of 
46.6, 88.2 and 87.8%, respectively), but demonstrated increased biofilm seeding at 15 
minutes of 18.7%.  
There was additionally one isolate of S. aureus (MSSA_10788), for which the maximum 
reduction in seeding was only 36% at 45 minutes (162 J/cm2). This result was repeatable, 
and it was noted that this isolate was highly pigmented, appearing orange on solid agar, 
compared to the yellow colouration of the other S aureus isolates. Additional planktonic 
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tests showed that the LD90 values were significantly higher in the orange pigmented strains 
than their yellow counterparts (p=0.003).  
This work has demonstrated that BL can be used to inactivate a wide range of clinical 
pathogens existing both planktonically and as mature biofilms. This technology therefore 
has real promise as a new antimicrobial agent for the healthcare setting and could 
ameliorate opportunistic infections indirectly by reducing the bacterial load on 
environmental surfaces, and directly within wounds. Although future studies are required 
(especially to investigate whether the exposure times could be reduced, and to test a larger 
panel of S. aureus strains), this study has already informed a significant part of a grant 
proposal investigating the use of BL for the treatment of civilian blast injuries.  
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Figure 13: Graph showing the mean average biofilm seeding results for all isolates when 
they were tested with blue light (BL) for 15, 30, 45 and 60 minutes. Optical density (OD) on the y-
axis refers to the mean average biofilm seeding for the isolates tested after exposure to blue light at the range of durations 
tested (in minutes) on the x-axis. A) A. baumannii isolates B) comparator Gram negative isolates, C) Gram positive isolates.  
Each data bar represents the mean average biofilm seeding from 24 technical replicates (NB:ENTCL_8004 and MSSA_10788 are averages of 48 technical replicates). The 
standard error of the mean is also plotted. The positive control represents the average biofilm seeding that occurred per isolate in the absence of BL treatment across 
all timepoints. The negative control represents the background level of optical density for the reagents used in the assay. ACI: A. baumannii, ENTCL: E. cloacae, STEMA: 
S. maltophilia, PSE: P. aeruginosa, EKIN: E. meningoseptica, EC: E. coli, MDR A: carbapenemase-producing K. pneumoniae,  MDR_B: carbapenem resistant K. 
pneumoniae, MRSA: methicillin-resistant S. aureus, MSSA: methicillin-sensitive S. aureus, EFM: E. faecium  
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Table 6: Table showing the average percentage (%) change in biofilm seeding in isolates 
exposed to blue light for 15, 30, 45 or 60 minutes compared to unexposed dark-incubated 
positive control biofilms 
 
Notes: % change values refer to the percentage increase (denoted by +), or decrease (denoted by -) in biofilm 
seeding for all the isolates exposed to blue light, compared to an unexposed dark-incubated positive control. 
Shading denotes reductions of at least 80% in biofilm seeding compared to the positive control. The ^ denotes 
the single isolate and single timepoint where there was not a significant change in biofilm biomass according to 
the Student’s t-test performed between treated and untreated data points with n-1 degrees of freedom.  
 
Isolate n 
Average change in biofilm seeding (%) with blue light 
exposure as follows 
 
15 min  
(54 J/cm2) 
30 min  
(108 J/cm2)  
45 min 
(162 J/cm2) 
60 min  
(216 J/cm2) 
 
ACI_616 24 -75.9 -92.4 -96.5 -94.5 
ACI_618 24 -39 -71.1 -85.6 -91.3 
ACI_642 24 -45.6 -69.8 -77.3 -76.3 
ACI_648 24 -43.7 -83 -78.2 -81.4 
ACI_659 24 -47.1 -88.6 -94.1 -94.3 
ACI_665 24 -53.9 -69.9 -82.5 -92 
ACI_671 24 -37.4 -60.6 -65.7 -79.9 
ACI_672 24 -31.1 -77.7 -76.5 -90.7 
ACI_698 24 -36.7 -87.3 -92.2 -93.7 
ACI_AYE 24 -41.9 -76.2 -86.7 -95.5 
ACI_C60 24 -60.4 -89 -93.3 -94.8 
ACI_19606 24 -93.5 -94.6 -93.2 -94.3 
ENTCL_525 24 -34.9 -86.1 -92.2 -92.6 
ENTCL_801 24 -61.3 -94.6 -95.6 -96.4 
ENTCL_804 48 +18.7 -46.6 -88.2 -87.8 
STEMA_529 24 -80.7 -81 -92.4 -95.1 
STEMA_551 24 -84.5 -95.1 -96.2 -94 
STEMA_558 24 -71 -93.3 -96.2 -94.7 
PSE_568 24 -83.9 -82.8 -87.2 -81.8 
PSE_PA01 24 -83.7 -86.2 -82.8 -89.5 
PSE_6749 24 -88.9 -90.3 -87.1 -88.9 
PSE_1054 24 -58.3 -90.7 -83.2 -84.3 
PSE_1586 24 -80.3 -92.0 -89.4 -88.8 
EKIN_502 24 -85.8 -94.8 -91.6 -86.5 
EC_073 24 -93.0 -94.6 -96.2 -96.2 
EC_042 24 -92.1 -91.3 -92.1 -93.4 
MDR_A 24 -87.4 -96.0 -89.2 -82.4 
MDR_B 24 -75.3 -95.0 -95.8 -94.3 
MRSA_508 24 -59.5 -58 -73.7 -83.3 
MRSA_520 24 -44.5 -57.7 -73.2 -78.8 
MRSA_531 24 -81.6 -91.2 -88 -93.7 
MSSA_10788 48 -5.0 ^  -30.9 -36.3 -34.6 
MSSA_F77 24 -67.8 -79.6 -96.4 -92.0 
EFM_513 24 -66.3 -69.3 -68.2 -72.2 
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5 DISCUSSION 
 
5.1 Findings 
Using a series of high-throughput assays, the in vitro antimicrobial activity of a range of 
topical antimicrobial agents was assessed. All agents were effective against a large panel of 
clinically important nosocomial wound pathogens, in terms of their ability to prevent 
biofilm formation (all agents), and eradicate mature biofilms (NB: SH1 and AMDs were not 
tested in the MBEC assay). AA could prevent biofilm formation at concentrations of 
≤0.31%, and eradication of mature biofilms was observed for all isolates after 3 hours of 
exposure. SH1 prevented biofilm formation of 16 bacterial isolates at dilutions (from neat) 
of 1:2 to 1:128. Mature biofilms were highly susceptible to BL, with significant reduction in 
seeding observed for all isolates at all levels of exposure.  
In line with the aims and objectives, experiments were also conducted to compare the 
antimicrobial activity of the novel agents to conventionally used products (e.g. AA activity 
was compared to silver based AMDs used for burns patients, and SH1 compared to other 
honey-based wound care products). These demonstrated that the novel agents are not 
inferior (and in most cases were superior) to the conventional products in the in vitro 
setting, and therefore are promising antimicrobial agents, despite their humble and 
unassuming roots.  
 
5.2 New Insights 
In terms of new insights, antimicrobial activity against biofilms had not previously been 
assessed for SH1. The published findings therefore have been invaluable for the marketing 
of SH1, enabling a claim to be made of the product’s ‘antibiofilm’ properties (appendix 5.1), 
a patent application (appendix 5.2), and furthermore informing a clinical trial (appendix 
5.3).  
There was also limited data regarding the antimicrobial activity of BL against biofilms 
(especially those formed by wound pathogens). The published findings have prompted a 
large multi-centre collaboration investigating the use of visible light for the treatment of 
civilian blast injuries. Although as yet unpublished, the quantitative data also indicates that 
the BL treatment has anti-biofilm effects. The optical density measurements of the CV dye 
from the exposed biofilms was compared to the CV values of the positive control, and there 
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were statistically significant reductions (according to a paired Wilcoxon test) in the biomass 
of biofilm in the BL exposed biofilms. These data are shown in a series of box and whisker 
plots in figure 2 (appendix 5.4), with the statistical analysis (performed using R v3.3.2 [101] 
and other packages [102–104]) shown in table 1 (appendix 5.4). This is an important 
finding, as it suggests that the reductions in seeding seen following BL treatment most 
likely do represent some form of damage to the biofilm (instead of just a transient 
reduction in seeding). 
In terms of AA, the historical literature represents a series of case reports and poorly 
designed studies investigating the in vivo and in vitro antimicrobial activity for a range of 
bacteria and clinical conditions. Generally they report on the use of 1-5% AA for bacterial 
killing/eradication, and do provide some evidence in support of the clinical utility of AA 
[55,56,61,62]. However the small sample sizes, heterogeneous study designs, and limited 
information on the antibacterial nature of AA, makes it difficult to draw any conclusions. 
Although Fraise et al. [49] showed that AA can prevent the growth of important nosocomial 
pathogens, and that AA was effective at lower concentrations (e.g. 0.16% AA) than 
previous studies, a key limitation was the focus on planktonic growth. Bjarnsholt et al. [64] 
in part addressed this, contemporaneously to this study, showing that AA could eradicate 
preformed biofilms when used at 0.5% for P. aeruginosa and 1% for S. aureus.  
My published study confirmed that in the in vitro setting, AA can inhibit biofilm formation 
and eradicate pre-existing biofilms when used at very dilute concentrations (e.g. down to 
≤0.1%). Furthermore, through comparison studies with a range of AMDs, I have shown AA 
to be superior or equivalent in efficacy to market leaders [105].  
It is reasonable to envisage that there will be lower toxicity with lower concentrations of 
AA, and hence this study demonstrates that AA is a potential alternative to antibiotics and 
AMDs for preventing colonisation of burns, and may have a role in the management of 
burns in both developed and developing countries.  
 
5.3 Considerations 
The limitations of the in vitro assays must be acknowledged. The assays were conducted on 
a range of abiotic surfaces (e.g. plastic), using standardised growth conditions, and hence 
are unlikely to mimic biofilm formation and persistence in the in vivo setting. Malone et al. 
[17] address this in an elegant review, highlighting the complexities of biofilms, and the 
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large variation and influences on biofilm architecture from in vitro to in vivo settings (e.g. 
the host immunological response). Furthermore, it is considered by some [106] that the 
morphology and behaviour of biofilms in vivo are at least as different from in vitro, as the 
differences between biofilms and planktonic bacteria. Whilst these are valid concerns, I feel 
it is necessary and ethical to evaluate activity of agents using available tests before they are 
introduced into patient care (which currently occurs on an ad hoc basis often without any 
direct laboratory investigation). Therefore, I chose to attempt to demonstrate some in vitro 
antimicrobial activity to inform clinical colleagues who are choosing AM agents to use on 
an ad hoc basis in patients. This has also allowed progression towards clinical trials. Due to 
the difficultly in setting up clinical trials (and the medical device classification negating 
them as necessary), case reports are unfortunately abundant in the medical device field. A 
lot of trust is placed in these findings, although there is no guarantee that the reported 
clinical improvement was due to the AM agent in question, instead of being explained by 
some other form of treatment.  
For the in vitro tests, additional limitations concern how the endpoints were measured. CV 
binds to bacterial biomass, but does not differentiate between live and dead cells [107]. 
The OD of CV was used to assess the extent of biofilm formation, but cannot be used to 
assess viability, or whether cells persisting after exposure could then disperse. 
Furthermore, it was raised by a reviewer that interpretation of reduced seeding in the 
MBEC assay may only represent death of the outermost bacterial biofilm cells (and not the 
biofilm per se). A small sonication experiment was performed, demonstrating that the 
whole biomass of the biofilm is effectively killed with AA exposure (unpublished) (appendix 
5.5). Similar (unpublished) data exists for SH1 and for BL.  
Additionally, it is possible that the Student’s t-test performed to assess significance of 
differences between TAA-exposed wells compared to unexposed positive control wells may 
not have been entirely appropriate. This is because the test assumes that the data follows 
an approximately normal distribution, and has equal standard deviations between data 
sets. The suitability of this test however appears to be a grey area, with one statistician (an 
author for two of the papers) happy with this choice, and another independent statistician 
suggesting that a non-parametric test would have been better. Given the small and highly 
significant p-values obtained, I felt reassured that the significance would not be affected, 
however to address this, a subset of the data was reanalysed using non-parametric tests 
(which accept that the data are not normally distributed); the Mann Whitney U test, and 
the Wilcoxon Rank Sum test (performed using PRISM (version 7.0 [108]). These data are 
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shown in tables 2-5 in Appendix 5.6. Generally the p-values closely match those obtained 
using the Student’s t-test, and there is only one instance (MDR_D, MH, 1 in 3) where the p-
value has shifted from being significant (p<0.05) to insignificant. I am therefore satisfied 
that conclusions from the papers remain valid.  
As a simple assessment of antibacterial activity, all studies were performed using 
monomicrobial biofilms, although it is well recognised that the majority of clinically 
relevant biofilms are polymicrobial, and involve interactions that may affect overall biofilm 
function, physiology and general properties (e.g. enhanced resistance to antimicrobials in 
polymicrobial biofilms compared to monomicrobial) [109]. In recognition of this limitation, 
some additional experiments were performed to assess the antibacterial activity of AA on a 
range of polymicrobial biofilms. Using a method modified from Guggenheim et al. [48], 
mono- and polymicrobial biofilms of P. aeruginosa, A. baumannii, E. faecium, and S. aureus, 
were generated over a period of 72 hours, and the mature biofilms subjected to AA at a 
range of concentrations from 5% to 0.08%. AA was still effective when biofilms were 
polymicrobial, but the MBEC shifted to a value intermediate between the Gram-negative 
MBEC (0.63%), and Gram-positive (2.5%) (appendix 5.7). Of interest, fungi are also 
susceptible to AA, as revealed through a single (unpublished) experiment (data not shown), 
and more extensive testing from collaborators at the University of Birmingham [110].  
An additional limitation is that this work did not investigate the mechanism of action 
(MOA) for the test agents. There is some evidence of a possible biphasic response in some 
of the data, whereby exposure of the bacteria to sub-inhibitory levels of the TAA has 
resulted in increased biofilm production (for the MBIC experiment), or enhanced biofilm 
seeding (for the MBEC). Figure 10 shows the biphasic response seen when isolate PS_PA01 
was co-incubated with SH1 and MH. For both, there is an antimicrobial effect at the 
stronger dilutions of honey, followed by enhanced biofilm production at the strong (but 
sub-inhibitory) dilutions of honey (e.g. 1:16 for SH1), before biofilm production reduces to 
positive control levels. This response is also apparent in some of the AA data. To investigate 
this further, the biphasic response from two isolates (MSSA_10788 and ACI_19606) was 
analysed, and is shown in appendix 5.8. For ACI_19606 there does appear to be enhanced 
biofilm production for all replicates at 0.09% AA, however for MSSA_10788 the biphasic 
response appears to be more random, only occurring in 6 of the replicates, and absent 
from the other 6 (NB: these represent two separate experiments). For one isolate 
(ENTCL_804), there was also enhanced seeding of biofilms following treatment with BL. 
This has been observed elsewhere [111,112]  and is likely to represent a bacterial response 
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to a low level of stress which results in increased biofilm formation at some sub-lethal 
concentrations of an antimicrobial agent. This potential pro-biofilm impact should be 
considered when choosing concentrations of active agents for incorporation in dressings 
etc, as exposure to low levels may promote unintended consequences. Interestingly 
however, this may not be entirely detrimental from a treatment point of view, as in some 
case such as BL-treated organisms there was a switch to being susceptible to an antibiotic, 
when previously they were resistant. This is described generally in the literature [113], but 
the presence/absence of this response should be investigated further prior to clinical 
translation of the TAAs.  
Although MOAs are proposed in the literature for SH1 and BL, the MOA of weak organic 
acids is thought to involve a variety of mechanisms and is not just a consequence of their 
acidity [114,115]. Hughes & Webber [116] propose the MOA to be due to the lowering of 
the internal cytoplasmic pH, and an increase in acetate levels interfering with central 
metabolism of the cells [115,116].  
Bjarnsholt et al. [64] took 24-hour cultures of P. aeruginosa and treated them with 0.5% AA 
solutions with varying levels of pH (modified through the addition of NaOH). The test 
solutions ranged in pH from 4.33 to 6.0 and they found complete killing of all bacteria in 
the wells when the pH was ≤4.33. In my experiments, the pH of AA ranged from 2.48 at 5%, 
to 3.12 at 0.8%, with the lowest universally effective concentration of AA (0.31%) being at 
pH 2.9. To investigate pH effect further, a small MBIC experiment was performed to 
compare the antibacterial activity of AA (organic acid) vs hydrochloric acid HCl (inorganic 
acid), against two strains of P. aeruginosa, and two A. baumannii. The pH was matched for 
the neat solutions of each acid, and dilutions made as previously. The results indicate that 
at the same pH, HCl was unable to prevent biofilm formation, compared to AA which was 
effective at 0.31% (appendix 5.9). 
It is possible that a range of other in vitro biofilm formation models could have been used, 
e.g. open systems such as the CDC reactor (where biofilms are formed on disks present in a 
chemotactic media), and continuous flow cell systems/drip flow reactors (where biofilms 
are grown on glass and supplied with a continuous source of media). Roberts et al. [2] 
elegantly reviewed a range of biofilm models and evaluated their ability to reflect chronic 
infections. They comment that models involving the growth of biofilms on a surface do not 
reflect chronic wound infections, and are only applicable for foreign body infections. For 
chronic wound infections, it is proposed that porcine in vivo models are beneficial, due to 
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similarities in immune response, tissue structure, and wound healing processes [117,118]. 
Additionally they suggest an improved in vitro method that better represents in vivo 
conditions to be the ‘wound-like medium’ model [119], where biofilms are grown in a static 
medium of plasma, blood cells and broth, but are not attached to a surface. Additionally, 
Thøstrup et al. [120] used a mouse burn wound model to visualise the development of P. 
aeruginosa biofilms using PNA_FISH. Although useful, these tests would have increased 
complexity and costs considerably, and I wanted a simple method to quickly assess a range 
of novel antimicrobial agents. 
Although not considered vital for translation, it is important to understand the MOA of the 
antimicrobial agent, since this helps in the general acceptance of the agent as a concept, 
and so that the possibility of resistance development can be considered. There are reports 
in the literature of resistance developing to Manuka honey [121], and of bacterial 
pigmentation leading to reducing susceptibility to BL. In terms of the TAA, it may be that 
lower concentrations are better tolerated by patients, but that there are greater risks of 
resistance developing.  
 
5.4 Translational outcomes 
This body of work focussed on potential translation of novel antimicrobial agents from the 
bench to bedside, and to this end has prompted a number of clinical trials. Ethical approval 
for such trials would not have been possible without these in vitro data.  
For AA, a pilot feasibility trial is planned which aims to investigate the optimal 
concentration of AA (0.5 vs 2%) for the treatment of burns patients, in terms of tolerability 
and antibacterial effect. Patients with small burns will be dressed with AA dressings twice 
daily, and assessments made of pain on application of the AA and at intervals afterwards. 
Swabs will be collected daily from the burn wound (so bacterial loads can be assessed), and 
AA will be retrieved from the used dressings to assess remaining antibacterial activity. 
Patients will be followed up for 5 days (appendix 5.10), and the team hope to start 
recruitment towards the end of 2017.  
The trial planned for SH1 involves the recruitment of 15 patients with bilateral venous leg 
ulcers (of comparable size and shape) (appendix 5.3). Each ulcer would be dressed with 
either SH1 or an AMD, and then covered with a standard compression bandage. Dressings 
would be changed every 48 hours, and a microbiology swab collected (so that bacterial 
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loads can be assessed). Patients will be followed up for 6 weeks and ulcer healing 
compared between the treatment groups.  
 
5.5 Barriers to future developments 
It is hoped that these translational studies will address some of the uncertainties 
surrounding the delivery, dosage and routes of application of these agents. However, there 
are many barriers to overcome. These are elegantly covered by Malone et al. [17], who 
suggest a range of possible explanations for the slow progress in medically-relevant biofilm 
research.  
Politics and regulatory matters in the medical arena make the planning and conducting of 
trials very time consuming and labour intensive. As a research centre, we have been trying 
to set up the AA clinical trial for 3 years, but have encountered delays due to the inefficient 
NHS IRAS system, lack of support from clinical trials teams, and classification of AA by the 
MHRA as an ‘investigational medicinal product’ (IMP), rather than a medical device. The 
majority of AMDs are classified as medical devices, since they only provide an ancillary 
action on the wound. Consequently, there are less stringent requirements for much data 
on effectiveness, and this can often be kept out of the public domain. Although I 
understand the reasons for such tight regulation in clinical trials research, I find it hard to 
accept that a trial using dilute vinegar (a foodstuff that the general population ingest 
regularly), could encounter so many delays given the large set of data from case reports 
and laboratory findings which strongly suggest that AA can be an extremely cheap, 
effective and well tolerated treatment for biofilms in wounds. The potential impact of this 
treatment across the NHS is very large and this is a solution which is globally applicable and 
requires little resource or expertise to apply.  
Given the reduced requirements to demonstrate efficacy, little incentive exists for 
producers of medical devices to perform costly and complicated RCTs to test their product 
clinically, and many would be reluctant to fund a costly trial based on in vitro data.  
Furthermore the agent itself must be considered. Although a patent does exist for the use 
of AA in dressings and devices [122], AA is not attractive from a business point of view, 
since it is unlikely to give good financial returns.  
In addition to the confusing classification of biocides, there is no ‘target’ reference value 
which can be used to assess the ‘effectiveness’ of an anti-biofilm agent. This means that 
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claims of an agent being ‘anti-biofilm’ need to be carefully assessed and considered. 
Coupled to this, there is also no standard way to test anti-biofilm agents in the laboratory 
(therefore no consistency across research groups), and for in vivo trials, there is no gold 
standard way to monitor wounds for the presence of biofilms [123,124], or to monitor 
wounds for healing. All these factors result in vast heterogeneity, and make it very hard to 
design in vivo trials to adequately test new agents.   
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6 CONCLUSIONS 
 
Given the many threats posed by antimicrobial resistance [125], and the reducing numbers 
of effective conventional antibiotics, it is clear that we really do need to investigate 
alternative antibacterial agents to combat infections. Although there is now a lot of interest 
in developing new antibiotics, topical treatments appear to be constantly overlooked.  
Topical biocides (such as AA) potentially represent antibiotic-sparing treatment options, 
but more research, funding and support is needed to help with initial early in vitro testing 
and translational studies, since the current system is chronically underfunded and 
represents a regulatory and political minefield.   
 
Nevertheless, this body of work has highlighted that there are a number of alternative and 
simple antimicrobial agents that have shown promise in vitro for the treatment and 
eradication of biofilm infections caused by a range of important nosocomial wound 
pathogens. Clinical trials are planned for these agents, and it remains to be seen whether 
the in vitro findings will translate to the in vivo setting, where there is a complex interplay 
between host and pathogen, and many other factors that influence biofilm presence and 
persistence.   
  
 57 
 
7 REFERENCES 
 
[1] Percival SL, Finnegan S, Donelli G, Vuotto C, Rimmer S, Lipsky BA. Antiseptics for 
treating infected wounds: Efficacy on biofilms and effect of pH. Crit Rev Microbiol 
2016;42:293–309. 
[2] Roberts AEL, Kragh KN, Bjarnsholt T, Diggle SP. The Limitations of In Vitro 
Experimentation in Understanding Biofilms and Chronic Infection. J Mol Biol 
2015;427:3646–61.  
[3] Gambino M, Cappitelli F. Mini-review: Biofilm responses to oxidative stress. 
Biofouling 2016;32:167–78.  
[4] Nicolella C, van Loosdrecht MC, Heijnen JJ. Wastewater treatment with particulate 
biofilm reactors. J Biotechnol 2000;80:1–33. 
[5] Wu Y, Ding Y, Cohen Y, Cao B. Elevated level of the second messenger c-di-GMP in 
Comamonas testosteroni enhances biofilm formation and biofilm-based 
biodegradation of 3-chloroaniline. Appl Microbiol Biotechnol 2015;99:1967–76.  
[6] Rudrappa T, Biedrzycki ML, Bais HP. Causes and consequences of plant-associated 
biofilms. FEMS Microbiol Ecol 2008;64:153–66. 
[7] Mieszkin S, Callow ME, Callow JA. Interactions between microbial biofilms and marine 
fouling algae: a mini review. Biofouling 2013;29:1097–113.  
[8] Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sørensen SR, Moser C, Kühl M, et al. The 
in vivo biofilm. Trends Microbiol 2013;21:466–74.  
[9] Bowler, PG, Davies, BJ. The microbiology of acute and chronic wounds. Wounds 
1999;11:72–8. 
[10] Mihai MM, Holban AM, Giurcaneanu C, Popa LG, Oanea RM, Lazar V, et al. Microbial 
biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds 
and medical device-related infections. Curr Top Med Chem 2015;15:1552–76. 
[11] Høiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, Donelli G, et al. ESCMID guideline 
for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect Off 
Publ Eur Soc Clin Microbiol Infect Dis 2015;21 Suppl 1:S1-25.  
[12] Malone M, Bjarnsholt T, McBain AJ, James GA, Stoodley P, Leaper D, et al. The 
prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of 
published data. J Wound Care 2017;26:20–5.  
[13] Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin 
Microbiol Rev 2006;19:403–34.  
 58 
 
[14] Metcalf, D, Bowler, P, Parsons, D. Wound Biofilm and Therapeutic Strategies. Microb. 
Biofilms - Importance Appl., 2016, p. 271–98. 
[15] Kirketerp-Møller K, Jensen PØ, Fazli M, Madsen KG, Pedersen J, Moser C, et al. 
Distribution, organization, and ecology of bacteria in chronic wounds. J Clin Microbiol 
2008;46:2717–22.  
[16] Metcalf DG, Bowler PG. Biofilm delays wound healing: A review of the evidence. 
Burns Trauma 2013;1:5–12.  
[17] Malone M, Goeres DM, Gosbell I, Vickery K, Jensen S, Stoodley P. Approaches to 
biofilm-associated infections: the need for standardized and relevant biofilm methods 
for clinical applications. Expert Rev Anti Infect Ther 2017;15:147–56.  
[18] Westgate, S, Cutting, K. The role of microbial biofilms in chronic and acute wounds. 
Nurs Resid Care n.d.;13:518–21. 
[19] Percival SL, McCarty SM, Lipsky B. Biofilms and Wounds: An Overview of the 
Evidence. Adv Wound Care 2015;4:373–81.  
[20] Joo H-S, Otto M. Molecular basis of in vivo biofilm formation by bacterial pathogens. 
Chem Biol 2012;19:1503–13.  
[21] Toyofuku M, Inaba T, Kiyokawa T, Obana N, Yawata Y, Nomura N. Environmental 
factors that shape biofilm formation. Biosci Biotechnol Biochem 2015;80:7–12.  
[22] Kim PJ, Steinberg JS. Wound care: biofilm and its impact on the latest treatment 
modalities for ulcerations of the diabetic foot. Semin Vasc Surg 2012;25:70–4.  
[23] Evans LR, Linker A. Production and characterization of the slime polysaccharide of 
Pseudomonas aeruginosa. J Bacteriol 1973;116:915–24. 
[24] Juhas M, Eberl L, Tümmler B. Quorum sensing: the power of cooperation in the world 
of Pseudomonas. Environ Microbiol 2005;7:459–71.  
[25] Boyd A, Chakrabarty AM. Pseudomonas aeruginosa biofilms: role of the alginate 
exopolysaccharide. J Ind Microbiol 1995;15:162–8. 
[26] Percival SL, Hill KE, Malic S, Thomas DW, Williams DW. Antimicrobial tolerance and 
the significance of persister cells in recalcitrant chronic wound biofilms. Wound 
Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc 2011;19:1–9.  
[27] Gilbert P, Das J, Foley I. Biofilm susceptibility to antimicrobials. Adv Dent Res 
1997;11:160–7. 
[28] Conlon BP, Rowe SE, Lewis K. Persister cells in biofilm associated infections. Adv Exp 
Med Biol 2015;831:1–9.  
 59 
 
[29] Bjarnsholt T, Kirketerp-Møller K, Jensen PØ, Madsen KG, Phipps R, Krogfelt K, et al. 
Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen Off Publ 
Wound Heal Soc Eur Tissue Repair Soc 2008;16:2–10.  
[30] Anon. Silver dressings - do they work? Drug Ther Bull 2010:38–42. 
[31] Clinton A, Carter T. Chronic Wound Biofilms: Pathogenesis and Potential Therapies. 
Lab Med 2015;46:277–84.  
[32] Harper, DR, Parracho, HMRT, Walker, J, Sharp, R, Hughes, G, Werthen, M, et al. 
Bacteriophages and Biofilms. Antibiotics 2014;3:270–84. 
[33] Fey PD. Modality of bacterial growth presents unique targets: how do we treat 
biofilm-mediated infections? Curr Opin Microbiol 2010;13:610–5.  
[34] McDonnell, G., Russell, A.D. Antiseptics and Disinfectants: Activity, Action, and 
Resistance. Clin Microbiol Rev 1999;12:147–79. 
[35] Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity 
prevents bacterial biofilm development. Nature 2002;417:552–5.  
[36] Li X-H, Lee J-H. Antibiofilm agents: A new perspective for antimicrobial strategy. J 
Microbiol Seoul Korea 2017;55:753–66.  
[37] Dong Y-H, Gusti AR, Zhang Q, Xu J-L, Zhang L-H. Identification of quorum-quenching 
N-acyl homoserine lactonases from Bacillus species. Appl Environ Microbiol 
2002;68:1754–9. 
[38] Vuotto C, Longo F, Donelli G. Probiotics to counteract biofilm-associated infections: 
promising and conflicting data. Int J Oral Sci 2014;6:189–94.  
[39] Hughes KA, Sutherland IW, Jones MV. Biofilm susceptibility to bacteriophage attack: 
the role of phage-borne polysaccharide depolymerase. Microbiol Read Engl 1998;144 
( Pt 11):3039–47.  
[40] Ammons MCB. Anti-biofilm strategies and the need for innovations in wound care. 
Recent Patents Anti-Infect Drug Disc 2010;5:10–7. 
[41] Craigen B, Dashiff A, Kadouri DE. The Use of Commercially Available Alpha-Amylase 
Compounds to Inhibit and Remove Staphylococcus aureus Biofilms. Open Microbiol J 
2011;5:21–31.  
[42] Wolcott RD, Rumbaugh KP, James G, Schultz G, Phillips P, Yang Q, et al. Biofilm 
maturity studies indicate sharp debridement opens a time- dependent therapeutic 
window. J Wound Care 2010;19:320–8.  
[43] Prescription Services. NHS Business Services Authority. Pers Commun 2010. 
 60 
 
[44] Khundkar R, Malic C, Burge T. Use of Acticoat dressings in burns: what is the 
evidence? Burns J Int Soc Burn Inj 2010;36:751–8.  
[45] Polak, F, Clift, M, Bower, L, Sprange, K. Buyer’s Guide: Advanced Wound Dressings. 
London: Centre for Evidence-Based purchasing; 2008. 
[46] Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing 
wound infection. Cochrane Database Syst Rev 2010:CD006478.  
[47] Cavanagh MH, Burrell RE, Nadworny PL. Evaluating antimicrobial efficacy of new 
commercially available silver dressings. Int Wound J 2010;7:394–405.  
[48] Guggenheim M, Thurnheer T, Gmür R, Giovanoli P, Guggenheim B. Validation of the 
Zürich burn-biofilm model. Burns J Int Soc Burn Inj 2011;37:1125–33.  
[49] Fraise AP, Wilkinson M a. C, Bradley CR, Oppenheim B, Moiemen N. The antibacterial 
activity and stability of acetic acid. J Hosp Infect 2013;84:329–31.  
[50] BSI Standards Publication. BS EN 13727. Chemical disinfectants and antiseptics - 
quantitative suspension test for the evaluation of bactericial activity in the medical 
area - test methods and requirements (phase 2, step 1). 2012. 
[51] European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the 
European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 
Determination of minimum inhibitory concentrations (MICs) of antibacterial agents 
by broth dilution. Clin Microbiol Infect 2003;9:1–7. 
[52] Baugh S, Ekanayaka AS, Piddock LJV, Webber MA. Loss of or inhibition of all multidrug 
resistance efflux pumps of Salmonella enterica serovar Typhimurium results in 
impaired ability to form a biofilm. J Antimicrob Chemother 2012;67:2409–17.  
[53] McGuiness W, Vella E, Harrison D. Influence of dressing changes on wound 
temperature. J Wound Care 2004;13:383–5.  
[54] Ceri H, Olson M, Morck D, Storey D, Read R, Buret A, et al. The MBEC Assay System: 
multiple equivalent biofilms for antibiotic and biocide susceptibility testing. Methods 
Enzymol 2001;337:377–85. 
[55] Ryssel H, Kloeters O, Germann G, Schäfer T, Wiedemann G, Oehlbauer M. The 
antimicrobial effect of acetic acid--an alternative to common local antiseptics? Burns J 
Int Soc Burn Inj 2009;35:695–700.  
[56] Phillips I, Lobo AZ, Fernandes R, Gundara NS. Acetic acid in the treatment of 
superficial wounds infected by Pseudomonas aeruginosa. Lancet Lond Engl 
1968;1:11–4. 
 61 
 
[57] McManus AT, Mason AD, McManus WF, Pruitt BA. Twenty-five year review of 
Pseudomonas aeruginosa bacteremia in a burn center. Eur J Clin Microbiol 
1985;4:219–23. 
[58] Smith DT. Causes and treatments of otitis media; I. Observations on 205 cases 
occuring in 613 consecutive hospital admissions. JAMA Paediatr 1924;28. 
[59] Currence WW. Acetic acid aerosol in treatment of purulent bronchiectasis due to 
Pseudomonas aeruginosa. AMA Am J Dis Child 1952;83:637–41. 
[60] Kass EH, Sossen HS. Prevention of infection of urinary tract in presence of indwelling 
catheters; description of electromechanical valve to provide intermittent drainage of 
the bladder. J Am Med Assoc 1959;169:1181–3. 
[61] Sloss JM, Cumberland N, Milner SM. Acetic acid used for the elimination of 
Pseudomonas aeruginosa from burn and soft tissue wounds. J R Army Med Corps 
1993;139:49–51. 
[62] Milner SM. Acetic acid to treat Pseudomonas aeruginosa in superficial wounds and 
burns. Lancet Lond Engl 1992;340:61. 
[63] Madhusudhan VL. Efficacy of 1% acetic acid in the treatment of chronic wounds 
infected with Pseudomonas aeruginosa: prospective randomised controlled clinical 
trial. Int Wound J 2016;13:1129–36.  
[64] Bjarnsholt T, Alhede M, Jensen PØ, Nielsen AK, Johansen HK, Homøe P, et al. 
Antibiofilm Properties of Acetic Acid. Adv Wound Care 2015;4:363–72.  
[65] Anon. Chronic wounds: advanced wound dressings and antimicrobial dressings 
(ESMPB2). NICE Evid Summ 2016. 
[66] British National Formulary. Appendix 5: Wound management products and 
elasticated garments. A5.3 Antimicrobbial Dressings. 2017. 
[67] Stone HH. Review of pseudomonas sepsis in thermal burns: verdoglobin 
determination and gentamicin therapy. Ann Surg 1966;163:297–305. 
[68] Miraftab M, Masood R, Edward-Jones V. A new carbohydrate-based wound dressing 
fibre with superior absorption and antimicrobial potency. Carbohydr Polym 
2014;101:1184–90.  
[69] Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral 
action of silver nanoparticles against HIV-1. J Nanobiotechnology 2010;8:1.  
[70] Bowler PG, Jones SA, Walker M, Parsons D. Microbicidal properties of a silver-
containing hydrofiber dressing against a variety of burn wound pathogens. J Burn 
Care Rehabil 2004;25:192–6. 
 62 
 
[71] Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection 
control and healing: review of the literature. Burns J Int Soc Burn Inj 2007;33:139–48.  
[72] Fong J. The use of silver products in the management of burn wounds: change in 
practice for the burn unit at Royal Perth Hospital. Prim Intent 2005;13:S16-22. 
[73] Fong J, Wood F. Nanocrystalline silver dressings in wound management: a review. Int 
J Nanomedicine 2006;1:441–9. 
[74] Collier M. Silver dressings: more evidence is needed to support their widespread 
clinical use. J Wound Care 2009;18:77–8. 
[75] Anon. “Evidence-based prescribing of advanced wound dressings for chronic wounds 
in primary care.” MeReC Bull 2010;21. 
[76] Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 
1979;6:65–70. 
[77] Armstrong DG. Manuka honey improved wound healing in patients with sloughy 
venous leg ulcers. Evid Based Med 2009;14:148.  
[78] Mizrahi, A, Lensky, Y. Honey as an antimicrobial agent. Bee Prod. Prop. Appl. 
Apitherapy, Plenum Press; 1996. 
[79] Tan HT, Rahman RA, Gan SH, Halim AS, Hassan SA, Sulaiman SA, et al. The 
antibacterial properties of Malaysian tualang honey against wound and enteric 
microorganisms in comparison to manuka honey. BMC Complement Altern Med 
2009;9:34.  
[80] Cooper, R, Molan, P, White, R. Antimicrobial activity of honey. Honey Mod. Wound 
Manag., Wounds UK; 2009. 
[81] Cooper, R. Honey as an effective antimicrobial treatment for chronic wounds: is there 
a place for it in modern medicine? Chronic Wound Care Manag Res 2014;1:15–22. 
[82] Dryden M, Lockyer G, Saeed K, Cooke J. Engineered honey: In vitro antimicrobial 
activity of a novel topical wound care treatment. J Glob Antimicrob Resist 
2014;2:168–72.  
[83] Dryden M, Dickinson A, Brooks J, Hudgell L, Saeed K, Cutting KF. A multi-centre clinical 
evaluation of reactive oxygen topical wound gel in 114 wounds. J Wound Care 
2016;25:140, 142–6.  
[84] Maclean M, MacGregor SJ, Anderson JG, Woolsey G. Inactivation of bacterial 
pathogens following exposure to light from a 405-nanometer light-emitting diode 
array. Appl Environ Microbiol 2009;75:1932–7.  
 63 
 
[85] Murdoch LE, McKenzie K, Maclean M, Macgregor SJ, Anderson JG. Lethal effects of 
high-intensity violet 405-nm light on Saccharomyces cerevisiae, Candida albicans, and 
on dormant and germinating spores of Aspergillus niger. Fungal Biol 2013;117:519–
27.  
[86] Maclean M, McKenzie K, Anderson JG, Gettinby G, MacGregor SJ. 405 nm light 
technology for the inactivation of pathogens and its potential role for environmental 
disinfection and infection control. J Hosp Infect 2014;88:1–11.  
[87] Dai T, Gupta A, Murray CK, Vrahas MS, Tegos GP, Hamblin MR. Blue light for 
infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond? Drug 
Resist Updat Rev Comment Antimicrob Anticancer Chemother 2012;15:223–36.  
[88] Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to 
infectious disease? Photochem Photobiol Sci Off J Eur Photochem Assoc Eur Soc 
Photobiol 2004;3:436–50.  
[89] Maclean M, Macgregor SJ, Anderson JG, Woolsey GA. The role of oxygen in the 
visible-light inactivation of Staphylococcus aureus. J Photochem Photobiol B 
2008;92:180–4.  
[90] Goldoni A. Porphyrins: fascinating molecules with biological significance. Sincrotrone 
TriesteSCpA, Trieste, Italy; 2002. 
[91] Enwemeka CS, Williams D, Hollosi S, Yens D, Enwemeka SK. Visible 405 nm SLD light 
photo-destroys methicillin-resistant Staphylococcus aureus (MRSA) in vitro. Lasers 
Surg Med 2008;40:734–7.  
[92] Murdoch LE, Maclean M, Endarko E, MacGregor SJ, Anderson JG. Bactericidal effects 
of 405 nm light exposure demonstrated by inactivation of Escherichia, Salmonella, 
Shigella, Listeria, and Mycobacterium species in liquid suspensions and on exposed 
surfaces. Scientific World Journal 2012; 137805. 
[93] Maclean M, Murdoch LE, MacGregor SJ, Anderson JG. Sporicidal effects of high-
intensity 405 nm visible light on endospore-forming bacteria. Photochem Photobiol 
2013;89:120–6.  
[94] Dai T, Gupta A, Huang Y-Y, Yin R, Murray CK, Vrahas MS, et al. Blue light rescues mice 
from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and 
mechanism of action. Antimicrob Agents Chemother 2013;57:1238–45.  
[95] Dai T, Gupta A, Huang Y-Y, Sherwood ME, Murray CK, Vrahas MS, et al. Blue light 
eliminates community-acquired methicillin-resistant Staphylococcus aureus in 
infected mouse skin abrasions. Photomed Laser Surg 2013;31:531–8.  
 64 
 
[96] Zhang Y, Zhu Y, Gupta A, Huang Y, Murray CK, Vrahas MS, et al. Antimicrobial blue 
light therapy for multidrug-resistant Acinetobacter baumannii infection in a mouse 
burn model: implications for prophylaxis and treatment of combat-related wound 
infections. J Infect Dis 2014;209:1963–71.  
[97] Noborio R, Nishida E, Kurokawa M, Morita A. A new targeted blue light phototherapy 
for the treatment of acne. Photodermatol Photoimmunol Photomed 2007;23:32–4.  
[98] Ganz RA, Viveiros J, Ahmad A, Ahmadi A, Khalil A, Tolkoff MJ, et al. Helicobacter pylori 
in patients can be killed by visible light. Lasers Surg Med 2005;36:260–5.  
[99] Bache SE, Maclean M, MacGregor SJ, Anderson JG, Gettinby G, Coia JE, et al. Clinical 
studies of the High-Intensity Narrow-Spectrum light Environmental Decontamination 
System (HINS-light EDS), for continuous disinfection in the burn unit inpatient and 
outpatient settings. Burns J Int Soc Burn Inj 2012;38:69–76.  
[100] Maclean M, Macgregor SJ, Anderson JG, Woolsey GA, Coia JE, Hamilton K, et al. 
Environmental decontamination of a hospital isolation room using high-intensity 
narrow-spectrum light. J Hosp Infect 2010;76:247–51.  
[101] R Core Team. R: A language and environment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria: 2016. 
[102] Frank E Harrell Jr. rms: Regression Modelling Strategies. 2017. 
[103] H Wickham. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 
2009. 
[104] Fox, J. Effect Displays in R for Generalised Linear Models. J Stat Softw;8:1–27. 
[105] Halstead FD, Rauf M, Bamford A, Wearn CM, Bishop JRB, Burt R, et al. Antimicrobial 
dressings: Comparison of the ability of a panel of dressings to prevent biofilm 
formation by key burn wound pathogens. Burns J Int Soc Burn Inj 2015;41:1683–94.  
[106] Benskin LLL. Limitations of in vitro antimicrobial dressings study. Burns J Int Soc Burn 
Inj 2016;42:1147–8.  
[107] Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharmacodynamic 
quantitative and qualitative model reveals the potent activity of daptomycin and 
delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother 
2013;57:2726–37.  
[108] Anon. GraphPad Prism version 7.00 for Windows. La Jolla California USA.  
[109] Burmølle M, Ren D, Bjarnsholt T, Sørensen SJ. Interactions in multispecies biofilms: do 
they actually matter? Trends Microbiol 2014;22:84–91.  
 65 
 
[110] Trzaska WJ, Correia JN, Villegas MT, May RC, Voelz K. pH manipulation as a novel 
strategy for treating mucormycosis. Antimicrob Agents Chemother 2015;59:6968–74.  
[111] Guffey JS, Payne W, Jones T, Martin K. Evidence of resistance development by 
Staphylococcus aureus to an in vitro, multiple stage application of 405 nm light from a 
supraluminous diode array. Photomed Laser Surg 2013;31:179–82.  
[112] Nussbaum EL, Lilge L, Mazzulli T. Effects of 630-, 660-, 810-, and 905-nm laser 
irradiation delivering radiant exposure of 1-50 J/cm2 on three species of bacteria in 
vitro. J Clin Laser Med Surg 2002;20:325–33.  
[113] Fila G, Kawiak A, Grinholc MS. Blue light treatment of Pseudomonas aeruginosa: 
Strong bactericidal activity, synergism with antibiotics and inactivation of virulence 
factors. Virulence 2017;8:938–58.  
[114] Roe AJ, McLaggan D, Davidson I, O’Byrne C, Booth IR. Perturbation of anion balance 
during inhibition of growth of Escherichia coli by weak acids. J Bacteriol 
1998;180:767–72. 
[115] Hirshfield IN, Terzulli S, O’Byrne C. Weak organic acids: a panoply of effects on 
bacteria. Sci Prog 2003;86:245–69. 
[116] Hughes G, Webber MA. Novel approaches to the treatment of bacterial biofilm 
infections. Br J Pharmacol 2017; 174:2237-2246. 
[117] Sullivan TP, Eaglstein WH, Davis SC, Mertz P. The pig as a model for human wound 
healing. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc 
2001;9:66–76. 
[118] Harrison F, Muruli A, Higgins S, Diggle SP. Development of an ex vivo porcine lung 
model for studying growth, virulence, and signaling of Pseudomonas aeruginosa. 
Infect Immun 2014;82:3312–23.  
[119] Dalton T, Dowd SE, Wolcott RD, Sun Y, Watters C, Griswold JA, et al. An in vivo 
polymicrobial biofilm wound infection model to study interspecies interactions. PloS 
One 2011;6:e27317.  
[120] Trøstrup H, Thomsen K, Christophersen LJ, Hougen HP, Bjarnsholt T, Jensen PØ, et al. 
Pseudomonas aeruginosa biofilm aggravates skin inflammatory response in BALB/c 
mice in a novel chronic wound model. Wound Repair Regen Off Publ Wound Heal Soc 
Eur Tissue Repair Soc 2013;21:292–9.  
[121] Camplin AL, Maddocks SE. Manuka honey treatment of biofilms of Pseudomonas 
aeruginosa results in the emergence of isolates with increased honey resistance. Ann 
Clin Microbiol Antimicrob 2014;13:19.  
 66 
 
[122] Givskov MC, Bjarnsholt T, Kirketerp-Moller K. Wound care products. WO 2011076216 
A3.  
[123] Hurlow J, Couch K, Laforet K, Bolton L, Metcalf D, Bowler P. Clinical Biofilms: A 
Challenging Frontier in Wound Care. Adv Wound Care 2015;4:295–301.  
[124] Percival SL, Vuotto C, Donelli G, Lipsky BA. Biofilms and Wounds: An Identification 
Algorithm and Potential Treatment Options. Adv Wound Care 2015;4:389–97.  
[125] Piddock LJV. Reflecting on the final report of the O’Neill Review on Antimicrobial 
Resistance. Lancet Infect Dis 2016;16:767–8.  
[126] Lund P, Tramonti A, De Biase D. Coping with low pH: molecular strategies in 
neutralophilic bacteria. FEMS Microbiol Rev 2014;38:1091–125.  
 
 
  
